UNCLASSIFIED

AD NUMBER

ADB266157

NEW LIMITATION CHANGE

TO

Approved for public release, distribution unlimited

FROM

Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Jul 2000. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.

AUTHORITY

USAMRMC ltr, dtd 15 May 2003

THIS PAGE IS UNCLASSIFIED

AD_____

Award Number: DAMD17-98-1-8076

TITLE: Beta-Adrenergic Receptors Regulating Growth and
       Replication of Breast Cancer Cells: Basic and Therapeutic
       Implications

PRINCIPAL INVESTIGATOR: Theodore Slotkin, Ph.D.

CONTRACTING ORGANIZATION: Duke University Medical Center
                          Durham, North Carolina 27710

REPORT DATE: July 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
               Fort Detrick, Maryland 21702-5012

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

20010509 111

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-98-1-8076
Organization: Duke University Medical Center
Location of Limited Rights Data (Pages):

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

04/10/01

REPORT DOCUMENTATION PAGE		Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE July 2000	3. REPORT TYPE AND DATES COVERED Annual (1 Jul 99 – 30 Jun 00)

4. TITLE AND SUBTITLE Beta-Adrenergic Receptors Regulating Growth and Replication of Breast Cancer Cells: Basic and Therapeutic Implications	5. FUNDING NUMBERS DAMD17-98-1-8076

6. AUTHOR(S)
Theodore Slotkin, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Duke University Medical Center Durham, North Carolina 27710 E-MAIL: t.slotkin@duke.edu	8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012	10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Jul 00). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.	12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)

This study explores β-adrenoceptors on breast cancer cells as a therapeutic target. MDA-MB-231 human breast cancer cells express high β_2-adrenoceptor levels that are linked to inhibition of mitosis through the production of cyclic AMP. The phosphodiesterase inhibitor, theophylline, reduced cell number and altered cellular morphology. In the current year, we evaluated the evaluated the effects of theophylline on macromolecule synthesis and indices of cell viability. Theophylline evoked a concentration- and time-dependent decrease in DNA synthesis. However, the decrease in cell number was greater than that predicted from mitotic arrest. Assessment of protein synthesis indicated a second effect separable from that on DNA synthesis; this was confirmed by decreased cell viability and adhesion. Exposure to the phosphodiesterase inhibitor, IBMX, in concentrations that produced inhibition of DNA synthesis equivalent to that seen with theophylline, elicited a smaller reduction in cell number. Theophylline also evoked specific changes in the expression or function of membrane-bound adenylyl cyclase activity, effects that are likely to contribute to sustained reactivity of these cells to other cAMP-related inhibitors of cell proliferation, such as isoproterenol. The multiple pharmacologic properties of theophylline, producing mitotic inhibition, cytotoxicity and altered signaling in MDA-MB-231 cells, provide insight into novel therapeutic strategies.

14. SUBJECT TERMS Breast Cancer – Beta-Adrenoceptors – Cyclic AMP – Mitosis – Theophylline	15. NUMBER OF PAGES 56
	16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_X_ Where copyrighted material is quoted, permission has been obtained to use such material.

_NA_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

_X_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

_____ 5/31/00
PI - Signature   /Date

3

Table of Contents

5. INTRODUCTION

A number of human breast cancers manufacture β-adrenergic receptors, for which there are drugs available that stimulate or inhibit their activity. The current study investigates the regulation and function of these receptors and identifies factors that can promote the ability of the receptors to influence cell division. In normal cells, the receptors are linked to the genes that control cell division only during a discrete developmental period in which they first enhance, and then terminate cell replication. We hypothesize that the redifferentiation that accompanies carcinogenesis will render cells responsive in the same way as are developing cells, but without the subsequent loss of reactivity that normally occurs as cells mature. There are three Specific Aims: (1) to determine whether β-receptors are linked to protooncogene expression and to evaluate the ability of the receptors to downregulate or desensitize upon exposure to a stimulant (isoproterenol); (2) to determine whether factors that promote the activity of β-receptor signaling lead to altered protooncogene expression and inhibition of cell replication — inhibitors cAMP breakdown (theophylline), or glucocorticoids (dexamethasone); (3) to determine whether stimulation or blockade of β-receptors can be used to control cell replication. In extending these results to detection and novel treatment paradigms, biopsy can readily identify the presence of β-receptors on breast cancer cells, indicating patients in whom xanthine derivatives and β-receptor agonists may serve as a useful addition to surgical, chemotherapeutic and radiation interventions. Perhaps most importantly, because β-adrenergic control of protooncogene expression is "upstream" from cell cycle control, interventions aimed at receptor-driven events should still operate even after multidrug resistance appears.

6. BODY

<u>Relationship of progress to each task described in the original Statement of Work</u>:

The original Statement of Work contained the following tasks:

Task 1 — Dose-response and time-response curves for isoproterenol sensitization or desensitization of β-receptors and adenylyl cyclase. This was completed in year 1 and described in last year's progress report.

Task 2 — Dose-response and time-response curves for isoproterenol induction of c-*fos* protooncogene expression. This is scheduled for year 3.

Task 3 — Dose-response and time-response curves for isoproterenol effects on DNA synthesis and cell number. This was completed in year 1 and described in last year's progress report.

Task 4 — Dose-response and time-response curves for isoproterenol effects on nuclear labeling. This is scheduled for year 3.

Task 5 — Dose-response and time-response curves for isoproterenol sensitization or desensitization of β-receptors and adenylyl cyclase in the presence or absence of theophylline; and in the presence or absence of dexamethasone — contains all the elements of Tasks 1, 2, 3. The studies of dexamethasone were completed in year 1 and described in last year's progress report. The studies of theophylline constituted the efforts for year 2 and are presented in the current progress report (below).

Task 6 — Ability of propranolol to block stimulatory effects of isoproterenol — contains all the elements of Tasks 1, 2, 3. This was completed in year 1 and described in last year's progress report.

Thus, we have completed a major portion of the tasks originally outlined in this proposal, and we are completely on schedule — two tasks out of the original six remain for the third year of study. In the first year, we chose to concentrate first on the demonstration that isoproterenol treatment could indeed interfere with breast cancer cell replication. We switched from the originally-proposed cell line (CG-5) to another line (MDA-MB-231) when it became apparent that the latter actually had a much higher concentration of β-adrenoceptors, was more readily available, and had a more demonstrable, widespread distribution in human cancers. To remain within a unitary set of techniques for each phase of the study, our first year concentrated on cell replication, cell number, adenylyl cyclase and receptor regulation as the targets (Task 1, Task 3, and the corresponding sections of Tasks 5 and 6). In the course of the first year's studies, we made the unusual observation that, among all the treatments evaluated, theophylline had by far the greatest inhibitory effect on mitosis. Accordingly, we shifted our priorities to concentrate on elaborating the mechanism of action of theophylline as the primary task for year 2 (it was originally scheduled for year 3), and shifting the remaining two tasks to the third year.

The body of this report is divided into three sections: an Introduction to the problem, Methods, and Results. Discussion of the results obtained, their importance and implications, appear in Section 9 — Conclusions.

Introduction

The emergence of breast cancers that are estrogen-insensitive and that also have the capability of developing multidrug resistance emphasizes the need for the development of alternative therapies. One potential strategy is to target cell surface receptors that mediate increases in intracellular cAMP levels, an effect that, in many different cell types, leads to inhibition of cell replication and consequent tumor regression (1-3). To a large extent, cAMP in tumor cells thus recapitulates the role of this second messenger in normal cell development, namely termination of cell division in favor of cell differentiation (4-8). In a recent study (9), we found that replication of MDA-MB-231 human breast cancer cells, an estrogen-insensitive cell line, is inhibited by stimulation of β-adrenoceptors located on the cell membrane, and that the underlying mechanism

is stimulation of adenylyl cyclase activity, resulting in increased intracellular cAMP levels. β-Adrenoceptors are expressed on a variety of cancer cell lines derived from epithelial or secretory tumors (7,10-13), including a number of breast cancers (1,2,9,11,14-16). Nevertheless, there are also many cell lines that either do not express β-adrenoceptors, express only small concentrations of the receptors, or that respond to receptor stimulation by enhanced cell replication rather than inhibition (1,11,17). It might therefore be useful to explore mechanisms to raise intracellular cAMP levels that do not depend solely on the expression of β-adrenoceptors.

In our previous work with MDA-MB-231 cells (9), we compared the effects of β-adrenoceptor agonists with membrane-permeable cAMP analogs and with theophylline, which inhibits phosphodiesterase, the enzyme that mediates cAMP breakdown. The potential anticancer actions of theophylline or related xanthines were proposed over a decade ago (18), and a number of studies have shown that theophylline reduces cell division in a number of different cancer cell lines (19-21). Surprisingly, we found that theophylline had greater effects on mitosis and cell morphology in the MDA-MB-231 breast cancer line than did either a β-adrenoceptor agonist or cAMP analogs, suggesting extra effects of this xanthine derivative besides inhibition of phosphodiesterase. This view is reinforced by the dichotomy in the cAMP and theophylline responses of MCF-7 breast cancer cells, where cAMP enhances the mitotic response to prolactin, whereas theophylline blocks the response (22). Indeed, although phosphodiesterase inhibitors, like theophylline, reduce cell replication via the increase in cAMP levels, they clearly affect cell differentiation through multiple mechanisms (23). Theophylline has a number of important cellular actions other than phosphodiesterase inhibition, notably its activity toward adenosine receptors, and its ability to generate reactive oxygen species. Ordinarily, adenosine receptor stimulation is thought to enhance cancer cell replication by decreasing intracellular cAMP levels (24); however, theophylline and its derivatives possess a mixture of adenosine agonist-antagonist properties that can contribute to antitumor activity, but that depend on the differentiation state of the target cells (25). Since theophylline is a xanthine derivative, there is the further possibility of free radical generation via xanthine oxidase, with the formation of cytotoxic levels of nitric oxide and peroxynitrite (26). Free radicals produced by xanthine oxidase also affect cancer cell adhesion (27) and elicit DNA strand breaks (28,29).

In the present study, we have evaluated the effects of theophylline on MDA-MB-231 human breast cancer cells, concentrating on comparisons of antimitotic activity, cytotoxicity and cell adhesion characteristics, and have contrasted the effects of theophylline with 3-isobutyl-1-methylxanthine (IBMX), a derivative that also inhibits phosphodiesterase and generates free radicals, but that is relatively insensitive toward adenosine receptors (26).

Methods
MDA-MB-231 cells (Duke University Comprehensive Cancer Center, Durham, NC) were seeded at a density of 10^6 cells per 100 mm diameter dish and maintained in modified Minimum Essential Medium containing Earle's salts, 5% fetal bovine serum, 2 mM glutamine, 100 IU/mL of penicillin, 0.1 mg/mL of streptomycin and 5 μg/mL of insulin (all from Gibco, Grand Island,

NY). Cells were incubated with 7.5% CO_2 at 37° C and the medium was changed every 24h. Cells were examined at 100× magnification for counting and morphological features. Each experiment was repeated several times with separate batches of cells, after an average of five passages. Each passage and preparation was verified for morphology and growth rate. Cell viability was verified by exclusion of trypan blue. Treatment effects were always compared against concurrent control cultures from the same passage and batch of cells. Except as otherwise indicated, all drugs were obtained from Sigma Chemical Co. (St. Louis, MO).

Macromolecule synthesis and DNA content. To initiate the measurement of DNA or protein synthesis, the medium was changed to include 1 μCi/mL of [³H]thymidine (specific activity, 2 Ci/mmol; New England Nuclear, Boston, MA) or [³H]leucine (140 Ci/mmol; New England Nuclear). Incubations were carried out for 1 hr, after which the medium was aspirated and cells were harvested in 3.5 mL of ice-cold water. Duplicate aliquots of each sample were treated with 10% trichloroacetic acid (TCA) and sedimented at 1000 _ g for 15 min to precipitate macromolecules and the resultant pellet was washed once with TCA and, for measurements of DNA synthesis, with 75% ethanol. The final pellet was then hydrolyzed with 1 M KOH overnight at 37° C, neutralized with HCl and the DNA was then precipitated with ice-cold 5% TCA and sedimented at 1000 _ g for 15 min. The supernatant solution, containing the solubilized protein, was counted for or [³H]leucine incorporation. For measurement of radiolabeled DNA and for DNA content, the pellet from this final step was hydrolyzed in 5% TCA for 15 min at 90° C, resedimented, and an aliquot of the supernatant solution counted for [³H]thymidine incorporation. Another aliquot was assayed for DNA spectrophotometrically by absorbance at 260 nm. Previous work has demonstrated quantitative recovery of macromolecules by these techniques (30). Incorporation values were corrected to the amount of DNA present in each culture to provide an index of DNA synthesis per cell.

Adenylyl cyclase activity. The medium was removed and cells were washed once with ice-cold, calcium- and magnesium-free Earle's balanced salt solution. Fresh solution was added and the cells were scraped off the dish and sedimented at $40,000 \times g$ for 15 min. The pellet was resuspended (Polytron, Brinkmann Instruments, Westbury, NY) in 10 mM $MgCl_2$, and 50 mM Tris (pH 7.4) and the homogenate was sedimented at $40,000 \times g$ for 15 min. The pellets were dispersed with a homogenizer (smooth glass fitted with a Teflon pestle) in 250 mM sucrose, 1 mM EGTA, 10 mM Tris (pH 7.4). Aliquots of membrane preparation containing ≈20 μg protein were then incubated for 30 min at 30° C with final concentrations of 100 mM Tris-HCl (pH 7.4), 10 mM theophylline, 1 mM adenosine 5'-triphosphate, 10 mM $MgCl_2$, 1 mg bovine serum albumin, and a creatine phosphokinase-ATP-regenerating system consisting of 10 mM sodium phosphocreatine and 8 IU phosphocreatine kinase, and 10 μM GTP in a total volume of 250 μl. The enzymatic reaction was stopped by placing the samples in a 90-100° C water bath for 5 min, followed by sedimentation at $3000 \times g$ for 15 min, and the supernatant solution was assayed for cAMP using radioimmunoassay kits (Amersham Corp., Chicago, IL). Preliminary experiments showed that the enzymatic reaction was linear well beyond the assay time period and was linear with membrane protein concentration; concentrations of cofactors were optimal

Unpublished

and, in particular, the addition of higher concentrations of GTP produced no further augmentation of activity. In addition to evaluating basal activity, the maximal total activity of the adenylyl cyclase catalytic unit was evaluated with the response to 10 mM $MnCl_2$ (31).

The contributions of G-protein-linked processes to adenylyl cyclase were evaluated in two ways. First, to determine the net G-protein-linked response of adenylyl cyclase activity with maximal activation of all G-proteins, samples were prepared containing 10 mM NaF (31). Second, β-adrenoceptor-targeted effects mediated through the G-proteins were evaluated with 100 μM isoproterenol. The concentrations of all the agents used here have been found previously to be optimal for effects on adenylyl cyclase and were confirmed in preliminary experiments (31,32).

Data analysis. Data are presented as means and standard errors. For each study, treatment-related differences were first evaluated by a global ANOVA, incorporating all variables in a single test. For studies of adenylyl cyclase activity, multiple measurements were made from the same membrane preparation since several different stimulants were compared; in that case, stimulant was considered a repeated measure. Where significant treatment effects were identified with the global test, individual differences between treatment groups were established with Fisher's Protected Least Significant Difference. Significance for all tests was assumed at $p < 0.05$. For convenience, data are presented as a percentage of control values but statistical significance was always assessed on the unmanipulated data. Where multiple time points are presented in the same graph, the control groups are given as a single value (100%), but statistical comparisons were conducted only with the time-matched group appropriate to each treatment.

Results

As found previously (9), MDA-MB-231 cells grew in log-phase from 1 to 4 days after plating. The doubling time, based on cell counts and DNA content, was approximately 3 days, whereas the doubling of confluence was much quicker (1.5 days), indicating growth both by cell enlargement and replication (data not shown). Accordingly, drug treatments were initiated after one day in culture and were terminated at various times during the log-phase of growth.

Introduction of theophylline into the culture medium caused an immediate, concentration-dependent reduction in [³H]thymidine incorporation into DNA (Fig. 1). Significant inhibition was seen at 1 mM theophylline and inhibition was >50% at 10 mM. After extended exposure (24h), there was no change in the concentration threshold for inhibition of DNA synthesis but the effect at 10 mM increased to >95% inhibition. Whereas there were no immediate effects of theophylline on cell number as monitored by DNA content, levels were 25% subnormal by 24h after beginning exposure to the highest theophylline concentration; by 72h, the DNA content in the theophylline-treated cells was only $17 \pm 1\%$ of the control values ($p < 0.0001$, n=10 for each group).

To determine whether the effects of theophylline on macromolecule synthesis were specific for DNA, we next determined whether similar treatment would affect protein synthesis (Fig. 2). Twenty-four hours after beginning exposure to theophylline, there was a significant decrement in protein synthesis, with a lower threshold than had been seen for DNA synthesis: deficits were significant with as little as 0.1 mM theophylline. However, the maximal effect seen with 10 mM theophylline was not as great as for DNA synthesis: protein synthesis was reduced to 40% of control values, whereas inhibition of DNA synthesis was nearly total at that concentration and time.

The differences in the concentration-response curves for inhibition of DNA and protein synthesis suggested that theophylline might have additional effects besides antimitotic activity. Accordingly, we assessed cell number and viability after a 48h exposure to 10 mM theophylline (Fig. 3). Theophylline evoked nearly a 60% reduction in the total number of cells. Among the remaining cells, theophylline had adverse effects on viability, as assessed by two indices, detachment and exclusion of trypan blue. The proportion of cells detached from the surface of the culture dish was nearly tripled and there was a doubling of the proportion stained with trypan blue.

Theophylline possesses distinctly different pharmacological modalities, as a phosphodiesterase inhibitor, an adenosine receptor antagonist, and a xanthine. Therefore we conducted similar studies using IBMX, a phosphodiesterase inhibitor with much lower activity toward adenosine receptors. Because IBMX requires a solvent (0.1% DMSO) in order to dissolve in an aqueous medium, we compared untreated cells to cells exposed to DMSO alone, and to cells exposed to IBMX in DMSO vehicle (Fig. 4). With a 24h exposure, 1 mM IBMX evoked 80% inhibition of DNA synthesis, much greater than that seen at the same concentration of theophylline. Nevertheless, IBMX elicited only a 10% reduction in cell number, no greater than that seen with the much less effective theophylline treatment. Indeed, when compared to 10 mM theophylline, a concentration that produced roughly equivalent inhibition of DNA synthesis to that caused by 1 mM IBMX, the effect of IBMX on cell number was significantly less: $9 \pm 3\%$ reduction for IBMX, $26 \pm 1\%$ reduction for theophylline (p < 0.0001).

In our previous work (9), we showed that stimulation of cellular cAMP levels with a β-adrenoceptor agonist led to reductions in DNA synthesis, accompanied by desensitization at the level of receptor-mediated adenylyl cyclase activity. Accordingly, we evaluated whether theophylline, which inhibits cAMP breakdown, also targets the function of this signaling cascade. After a 48h exposure to 10 mM theophylline, basal adenylyl cyclase activity was significantly reduced but signaling mediated by the (-adrenoceptor stimulant, isoproterenol, was maintained. Similarly, the response to fluoride, which evokes maximal stimulation of the G-proteins that link the receptors to adenylyl cyclase, was unaffected despite the lowering of basal enzyme activity. The response to manganese, which stimulates adenylyl cyclase directly, without the requirement for receptors or G-proteins, was significantly enhanced by theophylline treatment.

FIGURE 1

Effects of Theophylline on DNA Synthesis
ANOVA: Treatment, p < 0.0001; Treatment x Time, p < 0.0001

DNA synthesis and content after 2 or 24h of theophylline exposure. Data represent means and standard errors obtained from 7-16 determinations at each concentration and time. Control [^{3}H]thymidine incorporation averaged 6000 dpm/µg DNA at 2h and 5100 at 24h; DNA content averaged 26 and 33 µg/dish, respectively. ANOVA across all concentrations and both time periods appears at the top of each panel, and asterisks denote individual values that differ from the corresponding control.

Effects of Theophylline on DNA Content
ANOVA: Treatment, p < 0.0001; Treatment x Time, p < 0.0001

FIGURE 2

Effects of Theophylline on Protein Synthesis
ANOVA: Treatment, p < 0.0001

Effects of 10 mM theophylline on protein synthesis, measured after a 24h exposure. Data represent means and standard errors obtained from 8 determinations at each concentration. Control [^{3}H]leucine incorporation averaged 700 dpm/µg DNA. ANOVA across all concentrations appears at the top of the panel, and asterisks denote individual values that differ from the corresponding control.

11

Unpublished

FIGURE 3

Number of Cells



Percentage Detached

Percentage Nonviable

Cell number and viability after prolonged theophylline exposure. Data represent means and standard errors obtained from 16 determinations. Viability was determined by exclusion of trypan blue.

FIGURE 4

Effects of IBMX on DNA Synthesis and Content
ANOVA: Synthesis, p < 0.0001; Content, p < 0.002

DNA synthesis and content after exposure to 1 mM IBMX. Data represent means and standard errors obtained from 10 determinations for each condition. Because 0.1% DMSO vehicle was required to dissolve IBMX, values are compared for untreated cells (control), vehicle, and IBMX. ANOVA across all conditions appears at the top of the panel, and asterisks denote individual values that differ from the corresponding control or DMSO values.

FIGURE 5

Effects of Theophylline on Adenylyl Cyclase
ANOVA: Treatment x Measure, p < 0.0001

Effects of exposure to 10 mM theophylline on adenylyl cyclase activity measured under basal conditions, or with addition of 100 μM isoproterenol, 10 mM sodium fluoride, or 10 mM manganese chloride. Data represent means and standard errors obtained from 6 determinations for each stimulant. Control activities were: basal, 27 pmol/min per mg protein; isoproterenol, 70; fluoride, 59; manganese, 73. ANOVA across all measures appears at the top of the panel and asterisks denote individual values that differ from the corresponding control.

13   *Unpublished*

<center>7. Key research accomplishments</center>

❖ β-Adrenoceptors (βAR) are present on the cell surface in a number of different human breast cancer cell lines, including those that are nonresponsive to estrogen, and that are thus resistant to antiestrogen therapy.

❖ Exposure of MDA-MB-231 human breast cancer cells to isoproterenol, a βAR agonist, caused an immediate reduction in DNA synthesis, an effect mediated through the generation of cyclic AMP within the cell.

❖ Exposure of the cells to theophylline, which causes an even greater accumulation of cyclic AMP (through inhibition of phosphodiesterase, the enzyme that breaks down cyclic AMP), evoked total mitotic arrest and a profound reduction in cell number

❖ Theophylline not only arrested cell division, but also evoked cell death through a combination of cytotoxicity and oxidative stress.

❖ Because theophylline did not evoke desensitization of adenylyl cyclase, this drug can be used in conjunction with β-agonists to arrest the division of MDA-MB-231 breast cancer cells and to evoke cell death.

❖ Therapies targeting βAR and cyclic AMP may offer a chance to slow the growth and spread of some estrogen nonresponsive breast cancers. Since the effects on the cancer cells do not desensitize, whereas effects on normal cells do, effective regimens may be designed that minimize side effects. Attacking a cell surface receptor and its intracellular signaling molecules should remain an effective approach even after the emergence of multidrug resistance, which reduces the effectiveness only of drugs targeting intracellular sites.

<center>8. Reportable outcomes</center>

<u>Publication:</u> Slotkin, T.A., J. Zhang, R. Dancel, S.J. Garcia, C. Willis and F.J. Seidler, β-Adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells, *Breast Cancer Research and Treatment* **60**: 153-166, 2000.

<u>Manuscript:</u> Slotkin, T.A. and F.J. Seidler, Antimitotic and cytotoxic effects of theophylline in MDA-MB-231 human breast cancer cells. *Breast Cancer Research and Treatment*, submitted.

<center>9. Conclusions</center>

In our previous work with MDA-MB-231 cells, we found that increasing the intracellular cAMP concentration led to a decrease in mitosis, so that membrane-permeable cAMP analogs, a β-

<center>14</center>

adrenoceptor agonist (isoproterenol), or a phosphodiesterase inhibitor (theophylline), all led to a decrease in cell number (9). However, theophylline was far more effective than any other treatment and moreover, induced major morphologic changes not seen with the other agents. The current results indicate that theophylline has collateral actions that affect cell number and differentiate state. A comparison of the results of inhibition of DNA synthesis by theophylline, and the eventual reduction in cell number, provides the first indication of these additional effects. Based on the observed doubling time of MDA-MB-231 cells under our culture conditions, complete mitotic arrest for a 48h span would result in a 35-40% deficit in total cell number. However, 10 mM theophylline caused a significantly greater reduction: at 48h, the theophylline had only 40% of the control cell number; by 72h, measurements of DNA content indicated a deficit of over 80%, whereas mitotic arrest predicts only a 50% deficit. The unexpectedly large deficit in cell number is even more impressive in light of the fact that theophylline did not cause complete mitotic arrest, but rather elicited only 60% inhibition in the initial exposure period. Indeed, the fact that theophylline's effects on DNA synthesis intensify over a 24h span, implies that subsequent cellular changes are occurring that impact on cell division.

These results suggest that theophylline impacts events over and above the direct effect on cAMP and hence on cell replication. Our findings for protein synthesis and viability confirm this conclusion. Protein synthesis was reduced after a 24h exposure to theophylline at concentrations that did not affect DNA synthesis; furthermore, the entire concentration-response curve for effects on protein synthesis differed from that on DNA synthesis, as the maximal effect toward protein was considerably less. The studies with cell attachment and trypan blue exclusion provide further evidence that theophylline has an effect on cell viability in addition to its effects on replication. Theophylline exposure more than doubled the proportions of detached cells and of nonviable cells. It is unlikely that increased cAMP levels consequent to phosphodiesterase inhibition, can solely account for these findings; when we compared the effects of theophylline with those of IBMX, another xanthine-based, phosphodiesterase inhibitor, we obtained results indicative of actions separable from those on cAMP. A concentration (1 mM) of IBMX that produced inhibition of DNA synthesis equivalent to that seen with 1-10 mM theophylline failed to evoke a decrease in cell number beyond what would have been expected from mitotic inhibition, a situation very different from the effects of theophylline.

There are two likely supplementary mechanisms for theophylline's actions on cell viability: formation of oxidative free radicals, and actions at adenosine receptors. Theophylline is a substrate for xanthine oxidase, an enzyme known to generate free radicals and resultant cell damage (26-29). However, IBMX is also a xanthine and similarly induces free radical formation (26). Thus, either theophylline is more potent than IBMX in eliciting oxidative stress, or alternatively, it elicits cytotoxicity through collateral mechanisms, such as actions on adenosine receptors (25). Indeed, free radicals produced by xanthine oxidase tend to increase cancer cell adhesion (27), whereas a decrease was seen with theophylline in MDA-MB-231 cells, implying that free radicals alone cannot account for all aspects of theophylline's cytotoxicity. The alternative, namely a role of adenosine receptors in cancer cell replication, differentiation and cytotoxicity has been explored only sporadically. Activation of the receptors reduces cell

replication (24) and theophylline, acting as an antagonist, might then be expected to enhance, not inhibit mitosis. However, recent work indicates that under varying conditions of cell differentiation, theophylline derivatives possess mixed agonist-antagonist properties that can contribute to cytotoxicity (25). It is thus likely that the effects of theophylline on MDA-MB-231 cells represents the summation of three different mechanisms: phosphodiesterase inhibition, free radical formation, and actions at adenosine receptors.

All three mechanisms are also likely to contribute to the distinct changes in cell morphology and function seen after theophylline exposure (9). Oxidative stress itself induces cell differentiation (33); since the increase in cAMP evoked by phosphodiesterase inhibition also serves to switch cells from replication to differentiation (4-9), the combined effect can account for the profound change in morphology evoked by theophylline but not by treatments that have more modest effects restricted only to cAMP (9). The morphological changes elicited by theophylline suggest a profound change in differentiation state, and we obtained evidence for altered cell reactivity after theophylline exposure, another characteristic of differentiation. The adenylyl cyclase signaling cascade undergoes substantial changes during growth of MDA-MB-231 cells, characterized by a loss of basal enzyme activity but preservation of signaling mediated through membrane-bound β-adrenoceptors (9). Treatment of the cells with theophylline similarly evoked a decrease in basal enzyme activity with maintenance of the response to stimulation of β-adrenoceptors by isoproterenol, or to fluoride-induced stimulation of the G-proteins that couple the receptors to adenylyl cyclase. Furthermore, there was specific enhancement of the response to manganese, which operates directly on adenylyl cyclase itself, without the participation of receptors or G-proteins; this implies either that adenylyl cyclase is induced by theophylline, or alternatively, that there is a shift toward expression of a more active isoform. In either case, the promotional effect on adenylyl cyclase is likely to augment the effects of theophylline on cAMP generation, augmenting the effect of phosphodiesterase inhibition. The induction of adenylyl cyclase and preservation of the β-adrenoceptor effect throughout differentiation may contribute additionally to the maintained ability of isoproterenol to inhibit MDA-MB-231 cell replication in the face of receptor downregulation that would ordinarily limit the response, thus augmenting the antitumor effect of other potential therapeutic interventions (9).

The multiple pharmacologic properties of theophylline, producing mitotic inhibition, cytotoxicity and altered signaling in MDA-MB-231 cells, may provide insight into novel therapeutic strategies. In light of the antitumor effects seen here, it may be worthwhile to reexamine the potential chemotherapeutic use of xanthine derivatives.

<u>"SO WHAT"</u>
Regardless of the ancillary mechanisms involved in β-adrenoceptor-mediated inhibition of mitosis or in the cytotoxic and antimitotic effects of theophylline in MDA-MB-231 breast cancer cells, the fact that these drugs do arrest mitosis and lead to cell death, without loss of response despite receptor downregulation and desensitization, raises the possibility for therapeutic strategies employing these agents. The cell line studied here, for example, is estrogen-insensitive and is thus nonresponsive to standard antiestrogen therapies. Furthermore, interventions operating at

the level of cell surface receptors, such as β-adrenoceptors, do not require penetration of drug to the interior of the cell, and thus would not be subject to loss of effect from induction of transporters in multidrug resistance. From a mechanistic standpoint, receptor input and the associated cell signaling cascade (in this case, cyclic AMP) is "upstream" from genes, whose mutations lead to constitutive activation and cell proliferation; cyclic AMP generation could thus limit the net effects of adverse mutations on cell cycle control by restricting expression of these genes. Given that desensitization effectively terminates the physiological effects of β-agonists in normal cells, therapeutic interventions based on receptor targeting should have only short-term side effects relative to the maintenance of effect in the target cell population; furthermore, the pharmacokinetics and toxicity of β-agonists and theophylline are well-established, since these drugs have long been used to treat asthma or to arrest premature labor. Neurotransmitter and cell signaling-based therapeutic strategies should be explored in an *in vivo* model to establish the potential utility of this general approach. If successful, screening of human cancers for the presence of β-adrenoceptors, or indeed, of other cell surface receptors linked to cyclic AMP, along with *in vitro* evaluation of the response of the cells to receptor agonists or antagonists, may establish new treatment strategies.

10. REFERENCES

1.   Re G, Badino P, Girardi C, Di Carlo F: Effects of a β_2-agonist, clenbuterol, on cultured human (CG-5) breast cancer cells. Pharmacol Res 26:377-384, 1992

2.   Draoui A, Vandewalle B, Hornez L, REvillion F, Lefebvre J: β-Adrenergic receptors in human breast cancer: identification, characterization and correlation with progesterone and estradiol receptors. Anticancer Res 11:677-680, 1991

3.   Fentiman IS, Duhig T, Griffiths AB, Taylor-Papadimitriou J: Cyclic AMP inhibits the growth of human breast cancer cells in defined medium. Mol Biol Med 2:81-88, 1984

4.   Shmukier YB, Buznikov GA: Functional coupling of neurotransmitters with second messengers during cleavage divisions: facts and hypotheses. Perspect Dev Neurobiol 5:469-483, 1998

5.   Fennell M, Khawaja XZ, Cockett MI, Wood A: Enhanced neuronal differentiation of NTera-2 cells expressing neuronally restricted β_2 adrenergic receptor. Brain Res 799:243-249, 1998

6.   Claycomb WC: Biochemical aspects of cardiac muscle differentiation. J Biol Chem 251:6082-6089, 1976

7.   Mitra SP, Carraway RE: Synergistic effects of neurotensin and β-adrenergic agonist on 3 ',5 '-cyclic adenosine monophosphate accumulation and DNA synthesis in prostate cancer PC3 cells. Biochemical Pharmacology 57:1391-1397, 1999

8.   Chen J, Bander JA, Santore TA, Chen Y, Ram PT, Smit MJ, Iyengar R: Expression of $Q227L$-$G_{\alpha s}$ in MCF-7 human breast cancer cells inhibits tumorigenesis. Proc Natl Acad Sci 95:2648-2652, 1998

9. Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C, Seidler FJ: β-Adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Canc Res Treat in press, 2000

10. Ling L, Haraguchi K, Ohta K, Endo T, Onaya T: β_2-Adrenergic receptor mRNA is overexpressed in neoplastic human thyroid tissues. Endocrinology 130:547-549, 1992

11. Re G, Badino P, Novelli A, Girardi C, DiCarlo F: Evidence for functional β-adrenoceptor subtypes in CG-5 breast cancer cells. Pharmacol Res 33:255-260, 1996

12. MacEwan DJ, Milligan G: Up-regulation of a constitutively active form of the β_2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Lett 399:108-112, 1996

13. Canova C, Baudet C, Chevalier G, Brachet P, Wion D: Noradrenaline inhibits the programmed cell death induced by 1,25-dihydroxyvitamin D-3 in glioma. Eur J Pharmacol 319:365-368, 1997

14. Vandewalle B, Revillion F, Lefebvre J: Functional β-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 116:303-306, 1990

15. Marchetti B, Spinola PG, Pelletier G, Labrie F: A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of β-adrenergic receptors and correlation with tumor growth. J Steroid Biochem Mol Biol 38:307-320, 1991

16. Vazquez SM, Pignataro O, Luthy IA: α_2-Adrenergic effect on human breast cancer MCF-7 cells. Breast Canc Res Treat 55:41-49, 1999

17. Yand J, Guzman R, Richards J, Imagawa W, McCormick K, Nandi S: Growth factor and cyclic nucleotide-induced proliferation of normal and malignant mammary epithelial cells. Endocrinology 107:35-41, 1980

18. Weishaar RE, Cain MH, Bristol JA: A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem 28:537-545, 1985

19. Sandlund JT, Neckers LM, Schneller HE, Woodruff LS, Magrath IT: Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences. Cancer Res 53:127-132, 1993

20. Francis J, Thompson R, Bernal SD, Luk GD, Baylin SB: Effects of dibutyryl cyclic adenosine 3':5'-monophosphate on the growth of cultured human small-cell lung carcinoma and the specific cellular activity of L-dopa decarboxylase. Cancer Res 43:639-645, 1983

21. Lentini A, Kleinman HK, Mattioli P, Autuori-Pezzoli V, Nicolini L, Pietrini A, Abbruzzese A, Cardinali M, Beninati S: Inhibition of melanoma pulmonary metastasis by methylxanthines due to decreased invasion and proliferation. Melanoma Res 8:131-137, 1998

22. Shafie S, Brooks SC: Effect of prolactin on growth and the estrogen receptor level of human breast cancer cells (MCF-7). Cancer Res 37:792-799, 1977

23. Goto T, Matsushima H, Kasuya Y, Hosaka Y, Kitamura T, Kawabe K, Hida A, Ohta Y, Simizu T, Takeda K: The effect of papaverine on morphologic differentiation, proliferation and invasive potential of human prostatic cancer LNCaP cells. Intl J Urol 6:314-319, 1999

24. Lelievre V, Muller JM, Falcon J: Adenosine modulates cell proliferation in human colonic adenocarcinoma. I. Possible involvement of adenosine A1 receptor subtypes in HT29 cells. Eur J Pharmacol 341:289-297, 1998

25. Brooke SM, Sapolsky RM: A cautionary note: the actions of adenosine agonists and antagonists may be reversed under certain conditions in primary cultures. Brain Res Bull 51:307-312, 2000

26. Villiotou V, Deliconstantinos G, Nitric oxide, peroxynitrite and nitroso-compounds formation by ultraviolet A (UVA) irradiated human squamous cell carcinoma: potential role of nitric oxide in cancer prognosis. Anticancer Res 15:931-942, 1995

27. Suzuki K, Eguchi H, Koh YH, Park YS, Taniguchi NT, Acceleration of adhesion of cancer cells and neutrophils to endothelial cells in the absence of de novo protein synthesis: possible implication for involvement of hydroxyl radicals. Biochem Biophys Res Comm 257:214-217, 1999

28. Maeda H, Akaike T: Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Moscow) 63:854-865, 1998

29. Yoshikawa T, Kokura S, Tainaka K, Naito Y, Kondo M: A novel cancer therapy based on oxygen radicals. Cancer Res 55:1617-1620, 1995

30. Bell JM, Whitmore WL, Slotkin TA: Effects of α-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase, on nucleic acids and proteins in developing rat brain: critical perinatal periods for regional selectivity. Neuroscience 17:399-407, 1986

31. Chaudhry A, Granneman JG: Developmental changes in adenylyl cyclase and GTP binding proteins in brown fat. Amer J Physiol 261:R403-R411, 1991

32. Navarro HA, Kudlacz EM, Slotkin TA: Control of adenylate cyclase activity in developing rat heart and liver: effects of prenatal exposure to terbutaline or dexamethasone. Biol Neonate 60:127-136, 1991

33. Katoh S, Mitsui Y, Kitani K, Suzuki T: Hyperoxia induces the differentiated neuronal phenotype of PC12 cells by producing reactive oxygen species. Biochem Biophys Res Commun 241:347-351, 1997

11. APPENDICES

<u>Attachment — Publication:</u> Slotkin, T.A., J. Zhang, R. Dancel, S.J. Garcia, C. Willis and F.J. Seidler, β-Adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells, *Breast Cancer Research and Treatment* **60**: 153-166, 2000.

<u>Attachment — Manuscript:</u> Slotkin, T.A. and F.J. Seidler, Antimitotic and cytotoxic effects of theophylline in MDA-MB-231 human breast cancer cells. *Breast Cancer Research and Treatment*, submitted.

Report

β-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells

Theodore A. Slotkin, Jian Zhang, Ria Dancel, Stephanie J. Garcia, Carrie Willis, and Frederic J. Seidler
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA

Summary

MDA-MB-231 human breast cancer cells express high β-adrenoceptor levels, predominantly the β_2 subtype. Receptor stimulation by isoproterenol evoked immediate reductions in DNA synthesis which were blocked completely by propranolol and were of the same magnitude as effects elicited by high concentrations of 8-Br-cAMP. Isoproterenol-induced inhibition of DNA synthesis was maintained throughout several days of exposure, resulting in a decrement in total cell number, and the effects were augmented by cotreatment with dexamethasone; an even greater effect was seen when cAMP breakdown was inhibited by theophylline, with or without addition of isoproterenol. Despite the persistent effect of isoproterenol, receptor downregulation was evident with as little as 1 h of treatment, and over 90% of the receptors were lost within 24 h. Receptor downregulation was paralleled by homologous desensitization of the adenylyl cyclase response to β-adrenoceptor stimulation. Dexamethasone augmented the effects of isoproterenol on DNA synthesis but did not prevent receptor downregulation or desensitization. These results indicate that β-adrenoceptors are effectively linked, through cAMP, to the termination of cell replication in MDA-MB-231 human breast cancer cells, and that activation of only a small number of receptors is sufficient for a maximal effect. Novel pharmacologic strategies that focus on cell surface receptors operating through adenylyl cyclase may offer opportunities to combat cancers that are unresponsive to hormonal agents, or that have developed multidrug resistance.

Abbreviations: ANCOVA: analysis of covariance; ANOVA: analysis of variance; cAMP: cyclic adenosine-3′,5′-monophosphate

Introduction

In addition to their role as neurotransmitters and 'stress' hormones, catecholamines play a trophic role in the control of cell replication and differentiation in target cells that express adrenergic receptors. Lower organisms, such as sea urchins, overexpress norepinephrine, epinephrine, and other biogenic amines during critical developmental periods in which these amines control cell replication and differentiation [1]. In mammals, 'spikes' of adrenergic activity also modulate the rate of cell replication and differentiation and thus control the architectural modeling of adrenergic target tissues [2–6]. The importance of adrenergic con-

trol of mammalian cell development has recently been pointed out by the lethal effects of gene knockouts that eliminate the ability to synthesize norepinephrine or to express β-receptors; these animals die *in utero* from disruption of cardiac cell replication/differentiation and consequent dysmorphogenesis [7–9]. The critical period for adrenergic control of these events terminates as cells exit mitosis and approach terminal differentiation, so that the sensitivity to adrenergic effects on cell replication disappears in adulthood except for a few tissues that undergo continual renewal [4, 5, 10, 11].

It is, thus, of critical importance that, with carcinogenic redifferentiation, many cell types, including

epithelial cancers and cancers of secretory cells, re-express β-adrenergic receptors [12–16], which can once again resume their role in the control of cell replication [13, 16, 17]. In some cell lines, β-adrenergic stimulation elicits a small, promotional effect on cell replication [13, 17, 18], whereas in others, stimulation of these receptors and the consequent rise in intracellular cAMP levels inhibits mitosis [16, 19]. β-adrenoceptors on cancer cells, thus, recapitulate both the promotional and inhibitory roles of these receptors in cell replication seen in the development of normal cells [4–6, 20, 21]. Accordingly, it might be feasible to use β-adrenoceptor agonists or antagonists as pharmacologic interventions to control the replication of cancer cells. Indeed, short-term isoproterenol treatment of PC-3 prostate cancer cells inhibits DNA synthesis through β-receptor-mediated increases in cAMP [16], and direct administration of membrane permeable cAMP analogs inhibits tumorigenesis of MCF-7 breast cancer cells [19].

Receptor downregulation and desensitization are major problems limiting the potential use of β-receptor agonists to control cell replication. Ordinarily, prolonged receptor stimulation uncouples receptors from response elements (desensitization) and leads to internalization and sequestration of receptor proteins (downregulation), limiting the intensity and duration of cell stimulation [22]. During normal development, however, we have found that these processes are poorly developed so that responses are maintained or enhanced with agonist treatment [23–25]. This raises the possibility that loss of response may not occur in cancer cells as well. In the current study, we evaluate that hypothesis using MDA-MB-231 cells, a human breast cancer line that expresses high levels of β-adrenoceptors [26]. We report that prolonged β-agonist administration maintains inhibition of DNA synthesis and suppresses cell replication even when only a small proportion of the receptors remains, so that desensitization and downregulation do not limit the effect. We also show that effects are augmented by glucocorticoids, just as is true for normal cells during development [27], and also by inhibition of cAMP breakdown by theophylline.

Methods

MDA-MB-231 cells (Duke University Comprehensive Cancer Center, Durham, NC) were seeded at a density of 10^6 cells per 100 mm diameter dish and maintained in modified minimum essential medium containing Earle's salts, 5% fetal bovine serum, 2 mM glutamine, 100 IU/ml of penicillin, 0.1 mg/ml of streptomycin and 5 μg/ml of insulin (all from Gibco, Grand Island, NY). Cells were incubated with 7.5% CO_2 at 37°C, and the medium was changed every 24 h. Cells were examined at 100× magnification for counting and morphological features. Each experiment was repeated several times with separate batches of cells, after an average of five passages. Each passage and preparation was verified for morphology, growth rate, and the expression and/or function of β-adrenoceptors. Treatment effects were always compared against concurrent control cultures from the same passage and batch of cells. Except as otherwise indicated, all drugs were obtained from Sigma Chemical Co. (St. Louis, MO).

DNA synthesis and content

To initiate the measurement of DNA synthesis, the medium was changed to include 1 μCi/ml of [³H]thymidine (specific activity, 2 Ci/mmol; New England Nuclear, Boston, MA). Incubations were carried out for 1 h in the presence or absence of the appropriate drugs. At the end of that period, the medium was aspirated and cells were harvested in 3.5 ml of ice-cold water. Duplicate aliquots of each sample were treated with 10% trichloroacetic acid and sedimented at $1000 \times g$ for 15 min to precipitate macromolecules and the resultant pellet was washed once with additional trichloroacetic acid and with 75% ethanol. The final pellet was then hydrolyzed with 1 M KOH overnight at 37°C, neutralized with HCl, and the DNA was then precipitated with ice-cold 5% trichloroacetic acid and sedimented at $1000 \times g$ for 15 min. The pellet from this final step was hydrolyzed in 5% trichloroacetic acid for 15 min at 90°C, resedimented, and an aliquot of the supernatant solution counted for [³H]thymidine incorporation. Another aliquot was assayed for DNA spectrophotometrically by absorbance at 260 nm. Previous work has demonstrated quantitative recovery of DNA by these techniques [28]. Incorporation values were corrected to the amount of DNA present in each culture to provide an index of DNA synthesis per cell.

β-adrenoceptor binding

The medium was removed and cells were washed once with ice-cold, calcium- and magnesium-free Earle's balanced salt solution. Fresh solution was added and

the cells were scraped off the dish and sedimented at $40,000 \times g$ for 15 min. The pellet was resuspended (Polytron, Brinkmann Instruments, Westbury, NY) in 10 mM $MgCl_2$, and 50 mM Tris (pH 7.4) and the homogenate was sedimented at $40,000 \times g$ for 15 min. The pellets were dispersed with a homogenizer (smooth glass fitted with a Teflon pestle) in the same buffer.

Each assay contained membrane suspension corresponding to $\approx 5 \mu g$ of protein and 67 pM [^{125}I]iodopindolol (specific activity 2200 Ci/mmol, New England Nuclear) in a final volume of 250 μl of 145 mM NaCl, 2 mM $MgCl_2$, 20 mM Tris (pH 7.5) and 1 mM ascorbate. Nonspecific binding was evaluated with identical samples containing 100 μM isoproterenol, and was typically 15% of the total binding. In some experiments, displacement of ligand binding was carried out with the specific β_1-receptor antagonist, CGP20712A (Research Biochemicals International, Natick, MA) to identify the receptor subtype present on MDA-MB-231 cells. Scatchard determinations to identify changes in receptor number (B_{max}) or affinity (K_d) were carried out over a range of [^{125}I]iodopindolol concentrations from 0.02 to 1 nM.

Adenylyl cyclase activity

Cell membranes were prepared by the same procedure as for β-receptor binding, except that the buffer consisted of 250 mM sucrose, 1 mM EGTA, 10 mM Tris (pH 7.4). Aliquots of membrane preparation containing $\approx 20 \mu g$ protein were then incubated for 30 min at 30°C with final concentrations of 100 mM Tris–HCl (pH 7.4), 10 mM theophylline, 1 mM adenosine 5′-triphosphate, 10 mM $MgCl_2$, 1 mg bovine serum albumin, and a creatine phosphokinase-ATP-regenerating system consisting of 10 mM sodium phosphocreatine and 8 IU phosphocreatine kinase, and 10 μM GTP in a total volume of 25 μl. The enzymatic reaction was stopped by placing the samples in a 90–100°C water bath for 5 min, followed by sedimentation at $3000 \times g$ for 15 min, and the supernatant solution was assayed for cAMP using radioimmunoassay kits (Amersham Corp., Chicago, IL). Preliminary experiments showed that the enzymatic reaction was linear well beyond the assay time period and was linear with membrane protein concentration; concentrations of cofactors were optimal and, in particular, the addition of higher concentrations of GTP produced no further augmentation of activity. In addition to evaluating basal activity, the maximal total activity of the adenylyl cyclase catalytic unit was evaluated with the response to 10 mM $MnCl_2$ [29].

The contributions of G-protein-linked processes to adenylyl cyclase were evaluated in two ways. First, to determine the net G-protein-linked response of adenylyl cyclase activity with maximal activation of all G-proteins, samples were prepared containing 10 mM NaF in the presence of GTP [29]. Second, β-adrenoceptor-targeted effects mediated through the G-proteins were evaluated with 100 μM isoproterenol in the presence of GTP. The concentrations of all the agents used here have been found previously to be optimal for effects on adenylyl cyclase and were confirmed in preliminary experiments [29, 30].

Data analysis

Data are presented as means and standard errors. For each study, treatment-related differences were first evaluated by a global ANOVA, incorporating all variables in a single test. For studies of adenylyl cyclase activity, multiple measurements were made from the same membrane preparation since several different stimulants were compared; in that case, stimulant was considered a repeated measure. For studies of blockade of one drug by another, or of additive or synergistic effects, the combined effects were evaluated by two-factor ANOVA with the working hypothesis dependent upon a significant interaction between the two treatments. Where significant treatment effects were identified with the global test, individual differences between treatment groups were established with Fisher's protected least significant difference.

Scatchard plots were fitted by linear regression analysis and treatment-related differences were first compared by ANCOVA. Differences in maximal binding capacity (B_{max}) and the equilibrium dissociation constant (K_d, the reciprocal of receptor affinity) were then evaluated using Fisher's protected least significant difference.

Significance for main treatment effects was assumed at $p < 0.05$ and interaction terms were considered significant at $p < 0.1$ [31]. For convenience, some data are presented as a percentage of control values, but statistical significance was always assessed on the unmanipulated data. Where multiple time points are presented in the same graph, the control groups are given as a single value (100%), but statistical comparisons were conducted only with the time-matched group appropriate to each treatment.

Results

MDA-MB-231 cells were in log-phase growth from 1 to 4 days after plating, commencing at 25% confluence on day 1, through 80% confluence on day 4 (data not shown). Over this span, DNA synthesis was maintained at a nearly constant rate $(7000 \pm 500 \, dpm/\mu g$ DNA on day 1, 8100 ± 600 on day 4) and the number of cells, indicated by total DNA content, rose substantially $(27 \pm 2 \, \mu g$ DNA on day 1, $45 \pm 3 \, \mu g$ on day 4). The increase in confluence between 1 and 4 days (more than double) was larger than the increase in DNA content (65%), indicating that cell enlargement was also occurring over this span. Drug treatments were initiated after one day in culture and were terminated at various times during log-phase growth, no later than four days in culture.

Addition of as little as 1 nM of isoproterenol to the medium produced immediate and robust inhibition of DNA synthesis (Figure 1). The effect was maximal at 100 nM isoproterenol and was maintained throughout a 48 h exposure. At the end of that period, isoproterenol-treated cells showed a significant reduction in the number of cells, assessed by DNA content. The antimitotic effect was not related to cytotoxicity or loss of viability. Trypan blue exclusion indicated $95.1 \pm 0.5\%$ viability after a 48 h to $10 \, \mu M$ isoproterenol, compared to $96.2 \pm 0.5\%$ in controls (NS, $n = 8$ for each treatment group); similarly, isoproterenol did not increase the proportion of detached cells $(0.9 \pm 0.1\%$, compared to $1.5 \pm 0.3\%$ in controls). To demonstrate that the effects of isoproterenol on DNA synthesis were mediated through β-adrenoceptors stimulating the production of cAMP, a comparison was made with the membrane permeable cAMP analog 8-Br-cAMP, and with the effects of the β-receptor antagonist propranolol (Figure 2). Isoproterenol and 8-Br-cAMP were equally effective toward DNA synthesis, and the effect of isoproterenol was completely blocked by propranolol. Propranolol by itself had no effect.

In developing tissues, glucocorticoid administration can sensitize cells to β-adrenoceptor agonists by inducing receptor formation and by enhancing signaling components of the adenylyl cyclase cascade [27]. Accordingly, we examined whether dexamethasone enhances the ability of isoproterenol to inhibit DNA synthesis and to reduce the number of cells (Figure 3). By itself, a 24 or 48 h pretreatment with dexamethasone caused 20% inhibition of DNA synthesis and a significant reduction in cell number. When


Figure 1. Effects of isoproterenol treatment on DNA synthesis and content, presented as the percentage change from control values. Data represent means and standard errors obtained from 12–96 determinations for each concentration and time point. Isoproterenol was added for 2 h or 48 h, with inclusion of $[^3H]$thymidine for the final hour. ANOVA across all treatments appears at the top of each panel and asterisks denote individual treatments that differ significantly from the control.

cells were pretreated for 48 h with dexamethasone and then received a 2-h challenge with isoproterenol, the inhibitory effects on DNA synthesis were less than additive: the net effect on DNA synthesis was no greater than that of isoproterenol alone, and the effect on DNA content was not distinguishable from that seen with just the dexamethasone pretreatment. However, when both treatments were combined for 48 h, the net effects on DNA synthesis and DNA content were greater than those achieved by either treatment alone, albeit less than additive.

Inhibition of DNA Synthesis — 2 h

Figure 2. Effects of a 2-h treatment with isoproterenol (Iso), 8-bromo-cAMP (8Br), or propranolol (Pro) on DNA synthesis, presented as the percentage change from control values. Data represent means and standard errors obtained from 10–26 determinations for each concentration and time point. ANOVA across all treatments appears at the top of each panel; asterisks denote individual treatments that differ significantly from the control and the dagger denotes a significant difference between Pro + Iso and Iso alone. In addition, two-factor ANOVA for the effects of propranolol on the isoproterenol response indicated complete blockade ($p < 0.002$ for the main effect of isoproterenol, $p < 0.02$ for the main effect of propranolol, $p < 0.05$ for the interaction of the two treatments). None of the treatments produced a significant change in DNA content (data not shown).

In addition to measurements of DNA content, drug effects on the number and morphological characteristics of MDA-MB-231 cells were examined (Figures 4 and 5). In control cultures, cell morphology and size were essentially identical to those reported for the origination of the MDA-MB-231 line [32]. Sustained isoproterenol treatment reduced the total number of cells by over 20% and a comparable effect was seen for dexamethasone. Combined treatment with dexamethasone and isoproterenol had a comparably greater effect (30%), albeit not equivalent to the summation of the two individual effects. In order to maintain cAMP levels at the highest possible value, we also treated the cells with the phosphodiesterase inhibitor theophylline, with or without isoproterenol (Figure 4). Theophylline completely arrested mitosis, so that addition of isoproterenol had no further effect. Direct morphological examination (Figure 5) also confirmed that isoproterenol and dexamethasone, alone or in combination, reduced the number of cells. Again, theophylline caused massive reductions in cell number but in this case there were radical changes in cell morphology. The remaining cells were considerably larger

Inhibition of DNA Synthesis by Dexamethasone ± Isoproterenol

Reduction of DNA Content by Dexamethasone ± Isoproterenol

Figure 3. Effects of dexamethasone (Dex) alone or in combination with isoproterenol (Iso), on DNA synthesis and content, presented as the percentage change from control values. Data represent means and standard errors obtained from 11–54 determinations for each treatment. ANOVA across all treatments appears at the top of each panel; asterisks denote individual treatments that differ significantly from the control and the daggers denote significant differences between Dex 48 h + Iso 48 h, and the corresponding treatments with Dex or Iso alone. In addition, for DNA synthesis, two-factor ANOVA (dexamethasone 48 h × isoproterenol 2 h) indicates significant main effects of dexamethasone ($p < 0.0005$) and isoproterenol ($p < 0.0001$) but no interaction between the two treatments; with 48 h of both dexamethasone and isoproterenol treatment, there were significant main effects of both treatments ($p < 0.0001$ for each) as well as a significant interaction of dexamethasone × isoproterenol ($p < 0.002$). For DNA content, two-factor ANOVA (dexamethasone 48 h × isoproterenol 2 h) indicates a significant main effect of dexamethasone ($p < 0.009$) but no effect of isoproterenol; with 48 h of both dexamethasone and isoproterenol treatment, there were significant main effects of both treatments ($p < 0.0001$ for each).

than in the control group, indicating that the treatment did not prevent postmitotic cell growth and in addition, the cells assumed a distinct stellate appearance.

To determine whether the effects of isoproterenol are shared by all cancer cells expressing β-adrenoceptors, we compared the effects on MDA-MB-231 cells with those on rat C6 glioma cells (Figure 6). In contrast to the human breast cancer cells, C6 cells showed neither inhibition of DNA synthesis nor a reduction in DNA content over comparable periods.

Reduction of Cell Number After 72h Exposure to Isoproterenol, Dexamethasone, Theophylline

Figure 4. Effects of a 72-h treatment with isoproterenol (Iso), dexamethasone (Dex), or theophylline (Theo) on cell number, presented as the percentage change from control values. Data represent means and standard errors obtained from 10–22 determinations for each treatment. ANOVA across all treatments appears at the top of each panel. Asterisks denote individual treatments that differ significantly from the control; the dagger denotes a significant difference between Dex + Iso and either treatment alone; § denotes significant differences between theophylline with or without isoproterenol, as compared to all other treatments. In addition, two-factor ANOVA across the dexamethasone and isoproterenol treatments indicates significant main effects of each treatment alone ($p < 0.0001$) as well as a significant interaction of dexamethasone × isoproterenol ($p < 0.03$). Across the theophylline and isoproterenol groups, there were significant main effects of each treatment alone ($p < 0.0001$) as well as a significant interaction of theophylline × isoproterenol ($p < 0.0001$).

The maintenance of isoproterenol-induced inhibition of DNA synthesis in MDA-MB-231 cells over a 48-h span of continuous treatment suggested that either agonist-induced receptor downregulation or desensitization were not present in these cells, or alternatively, that stimulation of only a small number of receptors was sufficient to inhibit mitosis. Receptor downregulation can be selective for different subtypes and accordingly, we first evaluated which subtype was present in MDA-MB-231 cells. Using the β_1-selective antagonist CGP20712A, we found that displacement of [^{125}I]iodopindolol involved a single class of sites displaying an IC_{50} in the μM range (Figure 7). For contrast, we prepared cardiac cell membranes from one day old rats [27], which display predominance of the β_1-subtype [33]; in this preparation, CGP20712A displayed two IC_{50} values, one in the nM range corresponding to the major cardiac receptor population, and a minor component which, like the MDA-MB-231 cells, displayed an IC_{50} in the μM range. Accordingly, the subtype expressed by MDA-MB-231 cells is almost exclusively β_2.

We next determined whether isoproterenol treatment of MDA-MB-231 cells causes β_2-receptor downregulation and/or uncoupling of the receptors from

their ability to stimulate adenylyl cyclase. In untreated cells, adenylyl cyclase activity declined by over 50% during the span of log-phase replication (Figure 8). However, the adenylyl cyclase response to isoproterenol fell by a significantly smaller proportion than did any of the other measures and the concentration of β-receptors was maintained at the same level throughout replication and growth. Relative to total cyclase catalytic activity (Mn^{2+}), the isoproterenol response actually increased over the course of culturing. After 1 day in culture, isoproterenol evoked $75 \pm 3\%$ of the total catalytic response exemplified by Mn^{2+}, whereas after 3–4 days in culture, the two stimulations were indistinguishable: isoproterenol evoked $97 \pm 3\%$ of the total response ($p < 0.0001$ compared to the proportion after 1 day in culture).

Despite the fact that isoproterenol-induced inhibition of DNA synthesis was maintained throughout a 48-h drug exposure, receptor downregulation was apparent immediately upon introduction of the drug (Figure 9). A concentration-dependent reduction in receptor binding was evident within 1 h, with nearly complete downregulation by 24 h. Receptor binding then remained at 5–10% of control values throughout 72 h of exposure. Isoproterenol concentrations as low as 1 nM produced significant, albeit submaximal, reductions in receptor binding after 24 h of exposure. Scatchard analysis confirmed that the loss of receptor binding reflected a decrease in the number of receptors as measured by maximal binding, rather than a change in receptor affinity as monitored by the K_d. In additional studies, we found that a 2-h daily isoproterenol exposure was sufficient to cause full receptor downregulation. We treated cells for three days in succession, using $100\,\mu M$ isoproterenol for 2 h each day, followed in each case by 22 h without drug; 22 h after the third day's exposure, receptor binding was only $6 \pm 1\%$ of control values ($n = 6, p < 0.0001$). Similarly, even when we reduced the concentration to $1\,\mu M$ with exposure for 2 h per day over a 2-day span, receptor measurements made 22 h after the last exposure still indicated robust downregulation ($8 \pm 1\%$ of control, $n = 6, p < 0.0001$).

We also determined whether agonist-induced receptor downregulation was accompanied by loss of the adenylyl cyclase response to isoproterenol (Figure 10). Treatment of cells with $1\,\mu M$ isoproterenol for 2 h, which caused approximately a 25% reduction in β-receptor binding, also elicited a comparable loss of the membrane response of adenylyl cyclase to isoproterenol. However, changes at the level of

CONTROL

ISOPROTERENOL

DEXAMETHASONE

DEXAMETHASONE + ISOPROTERENOL

THEOPHYLLINE

THEOPHYLLINE + ISOPROTERENOL

Figure 5. Phase-contrast microscopic appearance of MDA-MB-231 cells after a 72-h treatment with isoproterenol, dexamethasone, or theophylline. Scale bar appears in the upper left panel.

G-protein function were evident: basal enzyme activity, measured in the presence of GTP, also showed significant and immediate reductions, and the response to maximal G-protein activation by fluoride was impaired by a small amount. After a 48-h exposure to isoproterenol, desensitization of the membrane adenylyl cyclase response to isoproterenol reached 75%, not quite as large as the degree of receptor downregulation; again, effects on basal adenylyl cyclase activity also were present, but were not as notable as the change in the β-receptor-mediated response. At no point did we note any decline in the expression or catalytic activity of adenylyl cyclase itself, as monitored by the effect of Mn^{2+}.

In light of the enhanced effect on cell replication of the combination of dexamethasone and isoproterenol treatment, we also examined their interaction at the levels of β-adrenoceptor binding and adenylyl cyclase activity. Pretreatment of cells with dexamethasone for 24 h had no effect on β-receptor binding (Figure 11, top panel). However, when the pretreatment was combined with a subsequent 4-h exposure to isoproterenol, it enhanced the downregulation caused by the receptor agonist. Dexamethasone

Effects of Isoproterenol on Rat C6 Glioma Cells

Figure 6. Effects of $10\,\mu M$ isoproterenol (Iso) on DNA synthesis and content in rat C6 glioma cells, presented as the percentage change from control values. Data represent means and standard errors obtained from 11–30 determinations for each time point. ANOVA across all treatments appears within each panel.

MDA-MB-231 Cells

One Day Old Rat Heart

Figure 7. Binding of $[^{125}\text{I}]$iodopindolol to β-adrenoceptors in cell membranes prepared from MDA-MB-231 cells and from one day old rat heart, and its displacement by the β_1-specific antagonist CGP20712A. Each data point represents an individual determination, shown as the percentage of values obtained in the absence of displacer. The $[^{125}\text{I}]$iodopindolol concentration was 67 pM.

**Adenylyl Cyclase Activity and β-Adrenoceptor Binding**

Figure 8. Adenylyl cyclase activity and β-adrenoceptor binding in MDA-MB-231 cells during cell replication and growth in culture. Cells were cultured for the indicated time periods and then membranes were isolated and enzyme activity determined under basal conditions or in the presence of $100\,\mu M$ isoproterenol (Iso), $10\,\text{mM}$ fluoride (F^-) or $10\,\text{mM}\,\text{Mn}^{2+}$. Data represent means and standard errors obtained from 6–24 determinations for each measurement at each time point. ANOVA across both time points and all stimulants appears within the panel and asterisks denote measures for which the values after 3–4 days in culture are significantly lower than the initial values. In addition, the cyclase response to isoproterenol declines less than the response to other stimulants ($p < 0.0001$).

had only small effects on adenylyl cyclase activity (Figure 11, bottom panel). By itself, dexamethasone lowered the membrane response to isoproterenol by a few percent. When dexamethasone pretreatment was superimposed on short-term isoproterenol treatment of the cells, basal adenylyl cyclase activity was inhibited slightly less than with isoproterenol alone and the fluoride response was inhibited somewhat more. However, the agonist-induced desensitization of the specific response to isoproterenol was just as prominent after dexamethasone pretreatment as it was without pretreatment.

Discussion

Among the epithelial, endocrine, and secretory cancer cell lines that express β-adrenoceptors, MDA-MB-231 human breast cancer cells exhibit comparatively high concentrations [13, 17, 26, 34, 35]. The B_{max} found here, 350 fmol/mg protein, exceeds the receptor concentration found in typical noradrenergic target tissues by over an order of magnitude [36] and is similar to the level found in brain regions enriched in noradrenergic projections. It is thus of critical

Time Course of Isoproterenol-Induced β-Adrenoceptor Downregulation

Concentration-Response Relationship for Isoproterenol-Induced β-Adrenoceptor Downregulation — 24 h Exposure

β-Receptor Binding

Figure 9. β-Adrenoceptor downregulation caused by isoproterenol treatment. Data represent means and standard errors obtained from the number of determinations shown in parentheses, determined as the percentage change from control values. In the top and middle panels, ANOVA across all time points or treatments appears at the top and asterisks denote individual values that differ significantly from the control. In the bottom panel, ANCOVA appears for the overall differences between Scatchard plots in control and isoproterenol-treated (Iso) cells.

Adenylyl Cyclase Activity after Isoproterenol Treatment

Figure 10. Desensitization of adenylyl cyclase evoked by exposure to $1\,\mu M$ isoproterenol. Cells were treated with isoproterenol for the indicated time period and then membranes were isolated and enzyme activity determined under basal conditions or in the presence of $100\,\mu M$ isoproterenol (Iso), $10\,mM$ fluoride (F^-), or $10\,mM$ Mn^{2+}. Data represent means and standard errors obtained from 6–12 determinations at each time point, determined as the percentage change from control values. ANOVA across all stimulants and both time points appears at the top and asterisks denote individual values that differ significantly from the control. Two-factor ANOVAs (treatment × time) were also assessed for each variable. Across both time points, basal activity was significantly reduced ($p < 0.0001$ for the main effect of isoproterenol), the response to isoproterenol was reduced in a time-dependent fashion ($p < 0.0001$ for the main effect, $p < 0.0001$ for the treatment × time interaction), the response to fluoride was reduced ($p < 0.0001$ for the main effect), and the response to Mn^{2+} was unaffected.

interest that stimulation of these receptors leads to immediate inhibition of DNA synthesis and, with prolonged exposure, reductions in the total number of cancer cells; inhibition of DNA synthesis is a reliable predictor of chemotherapeutic responses in breast cancer cells [37]. β-adrenoceptor-mediated inhibition of DNA synthesis was not shared by another cancer cell line, C6 rat glioma, that expresses a different β-receptor subtype at lower levels; whereas we found that MDA-MB-231 cells express β_2-receptors exclusively, C6 cells express primarily the β_1-subtype [38], but it is not clear whether this is the sole determinant of the role of β-adrenoceptors in the control of mitosis. Although there has been no systematic screening of breast cancer cell lines for β-adrenoceptor expression, these receptors have been identified in both estrogen-dependent and estrogen-independent types, including CG-5, BT-20, T47-D, VHB-1, and MCF-7 [13, 17, 26], as well as in tumors induced by administration by dimethylbenz(a)anthracene [34] and in unspecified collections of human breast cancer tissue samples [35]. In the two cases where receptor subtypes have

β-Adrenoceptor Binding After Treatment with Dexamethasone ± Isoproterenol

Adenylyl Cyclase Activity After 48 h Treatment with Dexamethasone ± Isoproterenol

Figure 11. Effects of dexamethasone (Dex) alone or in combination with isoproterenol (Iso), on β-adrenoceptor binding (top) and adenylyl cyclase activity (bottom). Cells were pretreated with 10 μM dexamethasone for 24 h (top) or 48 h (bottom) and were then exposed to 1 μM isoproterenol for 4 h. For adenylyl cyclase, enzyme activity was determined under basal conditions or in the presence of 100 μM isoproterenol (Iso), 10 mM fluoride (F^-), or 10 mM Mn^{2+}. Data represent means and standard errors obtained from 6–12 determinations for each treatment. For receptor binding, ANOVA across all treatments appears at the top; for adenylyl cyclase, ANOVA across all treatments and *in vitro* stimulants appears at the top, and lower order ANOVAs are shown for *in vitro* stimulant with each cluster of bars. Asterisks denote individual treatments that differ significantly from the control, and the daggers denote significant difference of combined treatment from the effects of dexamethasone or isoproterenol alone.

been identified, the $β_2$-subtype appears to predominate, just as found here [13, 35], although unlike our findings with MDA-MB-231 cells, some cell lines also make significant amounts of $β_1$-receptors [13]. In the CG-5 cell line, which expresses both the receptor subtypes, but at lower concentrations than those found here for MDA-MB-231 cells, administration of a β-

agonist evokes a biphasic response, with enhanced cell replication at low concentrations and inhibition at high concentrations. Nevertheless, it is generally the case that increased cAMP, whether induced by receptor activation or by addition of membrane-permeable cAMP analogs, inhibits cell replication and evokes tumor regression [17, 35] and that β-receptor expression is predictive of the overall pharmacologic response [34]. Accordingly, an understanding of the specific role of β-adrenoceptor function in different breast cancer cell lines will require evaluation of receptor concentration, subtype, the efficiency of coupling to the generation of cAMP, and, as evaluated here, the persistence of receptor activity in the face of agonist-induced receptor downregulation and desensitization.

Isoproterenol-induced inhibition of DNA synthesis in the MDA-MB-231 breast cancer cell line exhibited the characteristic properties of β-receptor actions mediated through adenylyl cyclase: complete blockade by propranolol, and sharing of the effect by a membrane-permeable cAMP analog. What was unexpected, however, was the fact that isoproterenol's effect did not disappear with prolonged treatment, and in fact, was maintained at exactly the same level as the initial effect. Ordinarily, β-adrenoceptor agonists elicit downregulation and desensitization over a time frame of a few minutes to hours [22], and therefore a loss of effect was expected here. The first hint of atypical regulation of β-receptor signaling was provided simply by monitoring adenylyl cyclase responses under control conditions. Over a course of several days in culture, adenylyl cyclase activity declined, accompanied by a loss of responsiveness to stimulants acting either at the level of β-receptors (isoproterenol), G-proteins (fluoride), or cyclase itself (Mn^{2+}). However, the enzymatic response to isoproterenol showed a smaller decline than for any other stimulant, that is, the β-adrenoceptor response actually increased relative to the total amount of catalytic activity. In fact, after 3–4 days in culture, isoproterenol elicited the maximal possible activation of adenylyl cyclase, since the activity was indistinguishable from that seen with addition of Mn^{2+}. In addition, the response to isoproterenol, which selectively activates G_s, was significantly greater than that to fluoride, which causes activation of both stimulatory and inhibitory G-proteins. The profound response to isoproterenol is unusual, since in most tissues, isoproterenol is incapable of eliciting adenylyl cyclase activation equaling that of direct G-protein or cyclase stimulants [23, 24, 30, 39]. The number of β-receptors also kept pace with cell divi-

sion and growth, so that the overall concentration of receptors remained unchanged throughout 4 days in culture, a period in which the number and size of cells increased substantially.

Given the maintenance of the ability of isoproterenol to inhibit DNA synthesis, we expected to see failure of receptor downregulation and/or desensitization, paralleling the situation during differentiation of normal cells possessing these receptors [23, 24, 30]. Surprisingly, isoproterenol caused immediate and robust receptor downregulation, accompanied by a parallel loss of the ability of receptor activation to stimulate adenylyl cyclase activity. Downregulation reached over 90% within 24 h and the adenylyl cyclase response was desensitized by 75% throughout the period in which inhibition of DNA synthesis was maintained. These results thus indicate that downregulation and desensitization do occur, but that the ability of receptor stimulation to inhibit DNA synthesis and cell acquisition requires activation of only a very small number of receptors. This raises the possibility that there may be adaptations in the signaling pathway downstream from receptors, G-proteins, and cyclase that serve to maintain the net effect of receptor stimulation. In keeping with this view, we have found that, during brain development, the initial stimulation of β-receptors 'programs' cAMP response elements so as to preserve or enhance the response of gene expression to adrenergic input [10, 39]. If similar events occur in MDA-MB-231 cells, then adaptations of downstream elements may preserve the effects on cell replication in the face of receptor downregulation and desensitization. Accordingly, a logical next step is to look at transcription factors and genes targeted by β-receptor stimulation and their role in the antimitotic effect of isoproterenol.

From both the standpoints of mechanism and therapeutics, our findings of augmented effects with cotreatment of dexamethasone or theophylline are potentially important. Initially, we expected dexamethasone to enhance the response to isoproterenol because glucocorticoids induce the synthesis of β₂-receptors in normal cells [40], especially during cell differentiation [27]. Dexamethasone treatment by itself inhibited DNA synthesis in MDA-MB-231 cells leading eventually to a reduction in cell number. In addition, when dexamethasone was combined with isoproterenol treatment, we saw even greater inhibition of DNA synthesis and loss of cells. However, when we examined the mechanism underlying the combined effect, we found that dexamethasone was

not capable of preventing agonist-induced β-receptor downregulation or desensitization; in fact, the combination of dexamethasone and isoproterenol produced a more-than-additive receptor downregulation. The disparity between the augmented effects of combined dexamethasone and isoproterenol treatment on DNA synthesis, which were less than additive, and effects directed toward receptor expression, which were synergistic and in a direction opposite to that expected from the effects on cell replication, indicate that dexamethasone must be acting on elements downstream from the receptor. Indeed, earlier work in replicating and differentiating cells indicates that glucocorticoids induce G-proteins and adenylyl cyclase [27]. In the current study, we found significant increases in total adenylyl cyclase activity (i.e. enhanced response to Mn^{2+}) after combined treatment with isoproterenol and dexamethasone; although dexamethasone and isoproterenol individually produced receptor uncoupling from adenylyl cyclase, dexamethasone did not augment the uncoupling caused by isoproterenol, even in the face of greater receptor downregulation. Obviously, post-receptor targets, including but not limited to adenylyl cyclase, play a pivotal role in maintaining the net response to receptor stimulation in the face of extensive downregulation. Additional downstream factors, such as protein kinase A and phosphorylated target proteins, are necessary to couple β-adrenoceptors to effects on cell replication and differentiation, and future studies will need to determine how glucocorticoids alter their expression and/or function to maintain the anti mitotic response to receptor stimulation.

The second cotreatment that we examined was the phosphodiesterase inhibitor, theophylline. This drug alone had the greatest effect on mitosis: after several days in culture, the number of cells appeared to be no greater than that originally plated. Theophylline has a greater effect than isoproterenol because it interrupts the ability of phosphodiesterase to limit the rise of intracellular cAMP levels. Indeed, the effects of theophylline are precisely the same as those seen for effects of prolonged elevations of cAMP during normal cell development, namely termination of cell division in favor of cell growth and differentiation [5, 41, 42], the same type of effects seen for cAMP in several other cancer cell lines [16, 19]. Accordingly, the theophylline-treated cells also showed gross enlargement as well as a morphological change to a stellate appearance, confirming the separability of effects on mitosis from those on cell growth and differentiation.

In light of the findings for isoproterenol and dexa-methasone, it is again possible that theophylline may influence gene expression downstream from cAMP generation, or alternatively, may act through other surface receptors (e.g. adenosine receptors) whose expression has not been explored in these cell lines.

Regardless of the ancillary mechanisms involved in β-adrenoceptor-mediated inhibition of mitosis in MDA-MB-231 breast cancer cells, the fact that inhibition does not disappear with receptor downregulation and desensitization raises the possibility for therapeutic strategies employing receptor agonists, alone or in combination with glucocorticoids and phosphodiesterase inhibitors. The cell line studied here, for example, is estrogen-insensitive and is thus nonresponsive to standard antiestrogen therapies. Furthermore, interventions operating at the level of cell surface receptors, such as β-adrenoceptors, do not require penetration of drug to the interior of the cell, and thus would not be subject to loss of effect from induction of transporters in multidrug resistance. Although theophylline was more effective than isoproterenol in reducing the number of cells in culture, it is distinctly possible that it would prove less effective with prolonged treatment *in vivo*. If theophylline acts through inhibition of phosphodiesterase, an intracellular locus, the cells may develop resistance, whereas if its actions are directed toward cell surface receptors (e.g. adenosine receptors), theophylline should maintain its effectiveness. From a mechanistic standpoint, input from receptors on the cell surface, like β-adrenoceptors, is 'upstream' from genes whose mutations lead to constitutive activation and cell proliferation [10, 43, 44]; receptor stimulation could thus limit the net effects of adverse mutations on cell cycle control by restricting expression of these genes. Given that desensitization effectively terminates the physiological effects of β-agonists in normal cells, therapeutic interventions based on receptor targeting should have only short-term side effects relative to the maintenance of effect in the target cell population. The concentrations of isoproterenol found to elicit inhibition of DNA synthesis and reductions of cell number in the current study (nM–μM) lie well within the range compatible with β-adrenergic effects in a wide variety of *in vivo* and *in vitro* systems [45] and approximates K_d values of isoproterenol for typical β-adrenoceptors [46, 47]. Consequently, it may be feasible to produce effective β-agonist concentrations for *in vivo* application; furthermore, the pharmacokinetics and toxicity of these agents are well-established. Neurotransmitter-

based therapeutic strategies should thus be explored in an *in vivo* model to establish the potential utility of this general approach. Indeed, similar work with neuropeptides targeting opioid receptors has established their ability to control cell growth and replication in colon cancer [48, 49]. In the current case, screening of human cancers for the presence of β-adrenoceptors, or other cAMP-linked neurotransmitter receptors, along with evaluation of the response of the cells to receptor agonists or antagonists, may establish new treatment strategies.

Acknowledgements

References

1. Buznikov GA, Kost AN, Berdysheva LV: The role of neuro-humours in early embryogenesis. 3. Pharmacological analysis of the role of neurohumours in cleavage divisions. J Embryol Exp Morphol 23: 549–569, 1970
2. Vernadakis A, Gibson DA: Role of neurotransmitter substances in neural growth. In: Dancis J, Hwang JC (eds) Perinatal Pharmacology: Problems and Priorities. Raven Press, New York, 1974, pp 65–76
3. Lovell J: Effects of 6-hydroxydopamine-induced norepinephrine depletion on cerebellar development. Dev Neurosci 5: 359–368, 1982
4. Slotkin TA, Whitmore WL, Orband-Miller L, Queen KL, Haim K: *Beta* adrenergic control of macromolecule synthesis in neonatal rat heart, kidney and lung: relationship to sympathetic neuronal development. J Pharmacol Exp Ther 243: 101–109, 1987
5. Claycomb WC: Biochemical aspects of cardiac muscle differentiation. J Biol Chem 251: 6082–6089, 1976
6. Slotkin TA, Levant B, Orband-Miller L, Queen KL, Stasheff S: Do sympathetic neurons coordinate cellular development in the heart and kidney? Effects of neonatal central and peripheral catecholaminergic lesions on cardiac and renal nucleic acids and proteins. J Pharmacol Exp Ther 244: 166–172, 1988
7. Rohrer DK, Desai KH, Jasper JR, Stevens ME, Regula DP, Barsh GS, Bernstein D, Kobilka BK: Targeted disruption of the mouse β1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci 93: 7375–7380, 1996
8. Thomas SA, Matsumoto AM, Palmiter RD: Noradrenaline is essential for mouse fetal development. Nature 374: 643–646, 1995

9. Zhou QY, Quaife CJ, Palmiter RD: Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 374: 640–643, 1995

10. Wagner JP, Seidler FJ, Schachat FH, Slotkin TA: Beta adrenergic control of c-fos protooncogene expression in developing rat brain regions. J Pharmacol Exp Ther 269: 1292–1299, 1994

11. Zeng T, Yamamoto H, Bowen E, Broverman RL, Nguyen KHT, Humphreys-Beher MG: Cell cycle control in isoproterenol-induced murine salivary acinar cell proliferation. Comp Biochem Physiol 115: 271–279, 1996

12. Ling L, Haraguchi K, Ohta K, Endo T, Onaya T: β_2-Adrenergic receptor mRNA is overexpressed in neoplastic human thyroid tissues. Endocrinology 130: 547–549, 1992

13. Re G, Badino P, Novelli A, Girardi C, DiCarlo F: Evidence for functional β-adrenoceptor subtypes in CG-5 breast cancer cells. Pharmacol Res 33: 255–260, 1996

14. MacEwan DJ, Milligan G: Up-regulation of a constitutively active form of the β_2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Lett 399: 108–112, 1996

15. Canova C, Baudet C, Chevalier G, Brachet P, Wion D: Noradrenaline inhibits the programmed cell death induced by 1,25-dihydroxyvitamin D-3 in glioma. Eur J Pharmacol 319: 365–368, 1997

16. Mitra SP, Carraway RE: Synergistic effects of neurotensin and β-adrenergic agonist on $3',5'$-cyclic adenosine monophosphate accumulation and DNA synthesis in prostate cancer PC3 cells. Biochem Pharmacol 57: 1391–1397, 1999

17. Re G, Badino P, Girardi C, Di Carlo F: Effects of a β_2-agonist, clenbuterol, on cultured human (CG-5) breast cancer cells. Pharmacol Res 26: 377–384, 1992

18. Yand J, Guzman R, Richards J, Imagawa W, McCormick K, Nandi S: Growth factor and cyclic nucleotide-induced proliferation of normal and malignant mammary epithelial cells. Endocrinology 107: 35–41, 1980

19. Chen J, Bander JA, Santore TA, Chen Y, Ram PT, Smit MJ, Iyengar R: Expression of Q227L-$G_{\alpha s}$ in MCF-7 human breast cancer cells inhibits tumorigenesis. Proc Natl Acad Sci 95: 2648–2652, 1998

20. Slotkin TA, Windh R, Whitmore WL, Seidler FJ: Adrenergic control of DNA synthesis in developing rat brain regions: effects of intracisternal administration of isoproterenol. Brain Res Bull 21: 737–740, 1988

21. Duncan CP, Seidler FJ, Lappi SE, Slotkin TA: Dual control of DNA synthesis by α- and β-adrenergic mechanisms in normoxic and hypoxic neonatal rat brain. Dev Brain Res 55: 29–33, 1990

22. Stiles GL: Mechanisms of receptor activation in adenylate cyclase. J Cardiovasc Pharmacol 14: S1–S5, 1989

23. Giannuzzi CE, Seidler FT, Slotkin TA: β-Adrenoceptor control of cardiac adenylyl cyclase during development: agonist pretreatment in the neonate uniquely causes heterologous sensitization, not desensitization. Brain Res 694: 271–278, 1995

24. Zeiders JL, Seidler FJ, Slotkin TA: Ontogeny of regulatory mechanisms for β-adrenoceptor control of rat cardiac adenylyl cyclase: targeting of G-proteins and the cyclase catalytic subunit. J Mol Cell Cardiol 29: 603–615, 1997

25. Zeiders JL, Seidler FJ, Iaccarino G, Koch WJ, Slotkin TA: Ontogeny of cardiac β-adrenoceptor desensitization mechanisms: agonist treatment enhances receptor/G-protein transduc-

tion rather than eliciting uncoupling. J Mol Cell Cardiol 31: 413–423, 1999

26. Vandewalle B, Revillion F, Lefebvre J: Functional β-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 116: 303–306, 1990

27. Slotkin TA, Lau C, McCook EC, Lappi SE, Seidler FJ: Glucocorticoids enhance intracellular signaling via adenylate cyclase at three distinct loci in the fetus: a mechanism for heterologous teratogenic sensitization? Toxicol Appl Pharmacol 127: 64–75, 1994

28. Bell TM, Whitmore WL, Slotkin TA: Effects of α-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase, on nucleic acids and proteins in developing rat brain: critical perinatal periods for regional selectivity. Neuroscience 17: 399–407, 1986

29. Chaudhry A, Granneman JG: Developmental changes in adenylyl cyclase and GTP binding proteins in brown fat. Amer J Physiol 261: R403–R411, 1991

30. Navarro HA, Kudlacz EM, Slotkin TA: Control of adenylate cyclase activity in developing rat heart and liver: effects of prenatal exposure to terbutaline or dexamethasone. Biol Neonate 60: 127–136, 1991

31. Snedecor GW, Cochran WG: Statistical Methods. Iowa State University Press, Ames, Iowa, 1967

32. Cailleau R, Young R, Olive M, Reeves WJ: Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53: 661–674, 1974

33. Slotkin TA, Lau C, Seidler FJ: β-Adrenergic receptor overexpression in the fetal rat: distribution, receptor subtypes and coupling to adenylate cyclase via G-proteins. Toxicol Appl Pharmacol 129: 223–234, 1994

34. Marchetti B, Spinola PG, Pelletier G, Labrie F: A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of β-adrenergic receptors and correlation with tumor growth. J Steroid Biochem Mol Biol 38: 307–320, 1991

35. Draoui A, Vandewalle B, Hornez L, Revillion F, Lefebvre J: β-Adrenergic receptors in human breast cancer: identification, characterization and correlation with progesterone and estradiol receptors. Anticancer Res 11: 677–680, 1991

36. Thai L, Galluzzo JM, McCook EC, Seidler FJ, Slotkin TA: Atypical regulation of hepatic adenylyl cyclase and adrenergic receptors during a critical developmental period: agonists evoke supersensitivity accompanied by failure of receptor downregulation. Pediatr Res 39: 697–707, 1996

37. Amadori D, Silvestrini R: Prognostic and predictive value of thymidine labelling index in breast cancer. Breast Cancer Res Treat 51: 267–281, 1998

38. Homburger V, Lucas M, Rosenbaum E, Vassent G, Bockaert J: Presence of both β_1- and β_2-adrenergic receptors in a single cell type. Mol Pharmacol 20: 463–469, 1981

39. Wagner JP, Seidler FJ, Lappi SE, McCook EC, Slotkin TA: Role of presynaptic input in the ontogeny of adrenergic cell signaling in rat brain: beta receptors, adenylate cyclase, and c-fos protooncogene expression. J Pharmacol Exp Ther 273: 415–426, 1995

40. Davies AO, Lefkowitz RJ: Regulation of β-adrenergic receptors by steroid hormones. Ann Rev Physiol 46: 119–130, 1984

41. Shmukler YB, Buznikov GA: Functional coupling of neurotransmitters with second messengers during cleavage divisions: facts and hypotheses. Perspect Dev Neurobiol 5: 469–483, 1998

42. Fennell M, Khawaja XZ, Cockett MI, Wood A: Enhanced neuronal differentiation of NTera-2 cells expressing neuronally restricted β_2 adrenergic receptor. Brain Res 799: 243–249, 1998

43. Mirossay L, Chastre E, Empereur S, Gespach C: Cyclic AMP-responsive gene transcription in cellular proliferation and transformation (review). Int J Oncol 1: 373–385, 1992

44. Moens U, Subramaniam N, Johansen B, Aarbakke J: The *c-fos* cAMP-response element: regulation of gene expression by a β_2-adrenergic agonist, serum and DNA methylation. Biochim Biophys Acta 1173: 63–70, 1993

45. Barnes CD, Eltherington LG: Drug Dosage in Laboratory Animals: A Handbook. Revised edition. Univ. of California Press, Berkeley, CA, 1973

46. Bian X, Seidler FJ, Olsen C, Raymond JR, Slotkin TA: Effects of fetal dexamethasone exposure on postnatal control of cardiac adenylate cyclase: β-adrenergic receptor coupling to G_s regulatory protein. Teratology 48: 169–177, 1993

47. Cros GH, Chanez PO, Michel A, Boucard M, Serrano J-J: Post-natal evolution of rat cardiac beta-adrenoceptors. Life Sci 43: 699–706, 1988

48. Zagon IS, Hytrek SD, Lang CM, Smith JP, McGarrity TJ, Wu Y, McLaughlin PJ: Opioid growth factor ([Met5]enkephalin) prevents the incidence and retards the growth of human colon cancer. Amer J Physiol 271: R780–R786, 1996

49. Hytrek SD, McLaughlin PJ, Lang CM, Zagon IS: Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone. Cancer Lett 101: 159–164, 1996

Address for offprints and correspondence: T.A. Slotkin, Box 3813 DUMC, Department of Pharmacology & Cancer Biology, Duke Univ. Med. Ctr., Durham, NC 27710, USA; *Tel.:* (919)681-8015; *Fax:* (919)684-8197; *E-mail:* t.slotkin@duke.edu

Antimitotic and Cytotoxic Effects of Theophylline
in MDA-MB-231 Human Breast Cancer Cells

Theodore A. Slotkin and Frederic J. Seidler

Department of Pharmacology & Cancer Biology

Duke University Medical Center

Durham, North Carolina 27710

Running title: Theophylline effects on MDA-MB-231 cells

Address for reprints: Dr. T.A. Slotkin

Box 3813 DUMC

Dept. of Pharmacology & Cancer Biology

Duke Univ. Med. Ctr.

Durham, NC 27710 USA

tel (919)681-8015

fax (919)684-8197

E mail: t.slotkin@duke.edu

Abbreviations: ANOVA, analysis of variance

cAMP, cyclic adenosine-3',5'-monophosphate

DMSO, dimethylsulfoxide

IBMX, 3-isobutyl-1-methylxanthine

SUMMARY

A variety of cancer cell lines, including MDA-MB-231 human breast cancer cells, exhibit mitotic inhibition by cAMP. In earlier work, we found that the phosphodiesterase inhibitor, theophylline, reduced the number of cells and altered cellular morphology. In the current study, we evaluated the evaluated the effects of theophylline on macromolecule synthesis and indices of cell viability. Theophylline evoked a concentration- and time-dependent decrease in DNA synthesis. However, the net decrease in cell number was greater than that predicted solely from mitotic arrest. Assessment of protein synthesis indicated a second effect of theophylline separable from that on DNA synthesis; this was confirmed by decreased cell viability and adhesion. Exposure of the cells to the phosphodiesterase inhibitor, IBMX, in concentrations that produced inhibition of DNA synthesis equivalent to that seen with theophylline, elicited a smaller reduction in cell number. Theophylline also evoked specific changes in the expression or function of membrane-bound adenylyl cyclase activity, effects that are likely to contribute to sustained reactivity of these cells to other cAMP-related inhibitors of cell proliferation, such as isoproterenol. The multiple pharmacologic properties of theophylline, producing mitotic inhibition, cytotoxicity and altered signaling in MDA-MB-231 cells, may provide insight into novel therapeutic strategies.

Index terms: Adenylyl cyclase

Cell replication

Cyclic AMP

DNA synthesis

Protein synthesis

Theophylline

Xanthine derivatives

INTRODUCTION

The emergence of breast cancers that are estrogen-insensitive and that also have the capability of developing multidrug resistance emphasizes the need for the development of alternative therapies. One potential strategy is to target cell surface receptors that mediate increases in intracellular cAMP levels, an effect that, in many different cell types, leads to inhibition of cell replication and consequent tumor regression (1-3). To a large extent, cAMP in tumor cells thus recapitulates the role of this second messenger in normal cell development, namely termination of cell division in favor of cell differentiation (4-8). In a recent study (9), we found that replication of MDA-MB-231 human breast cancer cells, an estrogen-insensitive cell line, is inhibited by stimulation of β-adrenoceptors located on the cell membrane, and that the underlying mechanism is stimulation of adenylyl cyclase activity, resulting in increased intracellular cAMP levels. β-Adrenoceptors are expressed on a variety of cancer cell lines derived from epithelial or secretory tumors (7,10-13), including a number of breast cancers (1,2,9,11,14-16). Nevertheless, there are also many cell lines that either do not express β-adrenoceptors, express only small concentrations of the receptors, or that respond to receptor stimulation by enhanced cell replication rather than inhibition (1,11,17). It might therefore be useful to explore mechanisms to raise intracellular cAMP levels that do not depend solely on the expression of β-adrenoceptors.

In our previous work with MDA-MB-231 cells (9), we compared the effects of β-adrenoceptor agonists with membrane-permeable cAMP analogs and with theophylline, which inhibits phosphodiesterase, the enzyme that mediates cAMP breakdown. The potential anticancer actions of theophylline or related xanthines were proposed over a decade ago (18), and a number of studies have shown that theophylline reduces cell division in a number of different cancer cell lines (19-21). Surprisingly, we found that theophylline had greater effects on mitosis and cell morphology in the MDA-MB-231 breast cancer line than did either a β-adrenoceptor agonist or cAMP analogs, suggesting extra effects of this xanthine derivative besides inhibition of phosphodiesterase. This view is reinforced by the dichotomy in the cAMP

and theophylline responses of MCF-7 breast cancer cells, where cAMP enhances the mitotic response to prolactin, whereas theophylline blocks the response (22). Indeed, although phosphodiesterase inhibitors, like theophylline, reduce cell replication via the increase in cAMP levels, they clearly affect cell differentiation through multiple mechanisms (23). Theophylline has a number of important cellular actions other than phosphodiesterase inhibition, notably its activity toward adenosine receptors, and its ability to generate reactive oxygen species. Ordinarily, adenosine receptor stimulation is thought to enhance cancer cell replication by decreasing intracellular cAMP levels (24); however, theophylline and its derivatives possess a mixture of adenosine agonist-antagonist properties that can contribute to antitumor activity, but that depend on the differentiation state of the target cells (25). Since theophylline is a xanthine derivative, there is the further possibility of free radical generation via xanthine oxidase, with the formation of cytotoxic levels of nitric oxide and peroxynitrite (26). Free radicals produced by xanthine oxidase also affect cancer cell adhesion (27) and elicit DNA strand breaks (28,29).

In the present study, we have evaluated the effects of theophylline on MDA-MB-231 human breast cancer cells, concentrating on comparisons of antimitotic activity, cytotoxicity and cell adhesion characteristics, and have contrasted the effects of theophylline with 3-isobutyl-1-methylxanthine (IBMX), a derivative that also inhibits phosphodiesterase and generates free radicals, but that is relatively insensitive toward adenosine receptors (26).

METHODS

MDA-MB-231 cells (Duke University Comprehensive Cancer Center, Durham, NC) were seeded at a density of 10^6 cells per 100 mm diameter dish and maintained in modified Minimum Essential Medium containing Earle's salts, 5% fetal bovine serum, 2 mM glutamine, 100 IU/mL of penicillin, 0.1 mg/mL of streptomycin and 5 μg/mL of insulin (all from Gibco, Grand Island, NY). Cells were incubated with 7.5% CO_2 at 37° C and the medium was changed every 24h. Cells were examined at 100× magnification for counting and morphological features. Each experiment was repeated several times with separate batches of cells, after an average of five passages. Each passage and preparation was verified for morphology and growth rate. Cell viability was verified by exclusion of trypan blue. Treatment effects were always compared against concurrent control cultures from the same passage and batch of cells. Except as otherwise indicated, all drugs were obtained from Sigma Chemical Co. (St. Louis, MO).

Macromolecule synthesis and DNA content. To initiate the measurement of DNA or protein synthesis, the medium was changed to include 1 μCi/mL of [^{3}H]thymidine (specific activity, 2 Ci/mmol; New England Nuclear, Boston, MA) or [^{3}H]leucine (140 Ci/mmol; New England Nuclear). Incubations were carried out for 1 hr, after which the medium was aspirated and cells were harvested in 3.5 mL of ice-cold water. Duplicate aliquots of each sample were treated with 10% trichloroacetic acid (TCA) and sedimented at 1000 × g for 15 min to precipitate macromolecules and the resultant pellet was washed once with TCA and, for measurements of DNA synthesis, with 75% ethanol. The final pellet was then hydrolyzed with 1 M KOH overnight at 37° C, neutralized with HCl and the DNA was then precipitated with ice-cold 5% TCA and sedimented at 1000 × g for 15 min. The supernatant solution, containing the solubilized protein, was counted for or [^{3}H]leucine incorporation. For measurement of radiolabeled DNA and for DNA content, the pellet from this final step was hydrolyzed in 5% TCA for 15 min at 90° C, resedimented, and an aliquot of the supernatant solution counted for [^{3}H]thymidine incorporation. Another aliquot was assayed for DNA spectrophotometrically by

absorbance at 260 nm. Previous work has demonstrated quantitative recovery of macromolecules by these techniques (30). Incorporation values were corrected to the amount of DNA present in each culture to provide an index of DNA synthesis per cell.

Adenylyl cyclase activity. The medium was removed and cells were washed once with ice-cold, calcium- and magnesium-free Earle's balanced salt solution. Fresh solution was added and the cells were scraped off the dish and sedimented at $40,000 \times g$ for 15 min. The pellet was resuspended (Polytron, Brinkmann Instruments, Westbury, NY) in 10 mM $MgCl_2$, and 50 mM Tris (pH 7.4) and the homogenate was sedimented at $40,000 \times g$ for 15 min. The pellets were dispersed with a homogenizer (smooth glass fitted with a Teflon pestle) in 250 mM sucrose, 1 mM EGTA, 10 mM Tris (pH 7.4). Aliquots of membrane preparation containing ≈ 20 μg protein were then incubated for 30 min at 30° C with final concentrations of 100 mM Tris-HCl (pH 7.4), 10 mM theophylline, 1 mM adenosine 5'-triphosphate, 10 mM $MgCl_2$, 1 mg bovine serum albumin, and a creatine phosphokinase-ATP-regenerating system consisting of 10 mM sodium phosphocreatine and 8 IU phosphocreatine kinase, and 10 μM GTP in a total volume of 250 μl. The enzymatic reaction was stopped by placing the samples in a 90-100° C water bath for 5 min, followed by sedimentation at $3000 \times g$ for 15 min, and the supernatant solution was assayed for cAMP using radioimmunoassay kits (Amersham Corp., Chicago, IL). Preliminary experiments showed that the enzymatic reaction was linear well beyond the assay time period and was linear with membrane protein concentration; concentrations of cofactors were optimal and, in particular, the addition of higher concentrations of GTP produced no further augmentation of activity. In addition to evaluating basal activity, the maximal total activity of the adenylyl cyclase catalytic unit was evaluated with the response to 10 mM $MnCl_2$ (31).

The contributions of G-protein-linked processes to adenylyl cyclase were evaluated in two ways. First, to determine the net G-protein-linked response of adenylyl cyclase activity with maximal activation of all G-proteins, samples were prepared containing 10 mM NaF (31). Second, β-adrenoceptor-targeted effects mediated through the G-proteins were evaluated with

100 μM isoproterenol. The concentrations of all the agents used here have been found previously to be optimal for effects on adenylyl cyclase and were confirmed in preliminary experiments (31,32).

Data analysis. Data are presented as means and standard errors. For each study, treatment-related differences were first evaluated by a global ANOVA, incorporating all variables in a single test. For studies of adenylyl cyclase activity, multiple measurements were made from the same membrane preparation since several different stimulants were compared; in that case, stimulant was considered a repeated measure. Where significant treatment effects were identified with the global test, individual differences between treatment groups were established with Fisher's Protected Least Significant Difference. Significance for all tests was assumed at $p < 0.05$. For convenience, data are presented as a percentage of control values but statistical significance was always assessed on the unmanipulated data. Where multiple time points are presented in the same graph, the control groups are given as a single value (100%), but statistical comparisons were conducted only with the time-matched group appropriate to each treatment.

RESULTS

As found previously (9), MDA-MB-231 cells grew in log-phase from 1 to 4 days after plating. The doubling time, based on cell counts and DNA content, was approximately 3 days, whereas the doubling of confluence was much quicker (1.5 days), indicating growth both by cell enlargement and replication (data not shown). Accordingly, drug treatments were initiated after one day in culture and were terminated at various times during the log-phase of growth.

Introduction of theophylline into the culture medium caused an immediate, concentration-dependent reduction in [^{3}H]thymidine incorporation into DNA (Fig. 1). Significant inhibition was seen at 1 mM theophylline and inhibition was >50% at 10 mM. After extended exposure (24h), there was no change in the concentration threshold for inhibition of DNA synthesis but the effect at 10 mM increased to >95% inhibition. Whereas there were no immediate effects of theophylline on cell number as monitored by DNA content, levels were 25% subnormal by 24h after beginning exposure to the highest theophylline concentration; by 72h, the DNA content in the theophylline-treated cells was only $17 \pm 1\%$ of the control values ($p < 0.0001$, n=10 for each group).

To determine whether the effects of theophylline on macromolecule synthesis were specific for DNA, we next determined whether similar treatment would affect protein synthesis (Fig. 2). Twenty-four hours after beginning exposure to theophylline, there was a significant decrement in protein synthesis, with a lower threshold than had been seen for DNA synthesis: deficits were significant with as little as 0.1 mM theophylline. However, the maximal effect seen with 10 mM theophylline was not as great as for DNA synthesis: protein synthesis was reduced to 40% of control values, whereas inhibition of DNA synthesis was nearly total at that concentration and time.

The differences in the concentration-response curves for inhibition of DNA and protein synthesis suggested that theophylline might have additional effects besides antimitotic activity. Accordingly, we assessed cell number and viability after a 48h exposure to 10 mM theophylline (Fig. 3). Theophylline evoked nearly a 60% reduction in the total number of cells. Among the

remaining cells, theophylline had adverse effects on viability, as assessed by two indices, detachment and exclusion of trypan blue. The proportion of cells detached from the surface of the culture dish was nearly tripled and there was a doubling of the proportion stained with trypan blue.

Theophylline possesses distinctly different pharmacological modalities, as a phosphodiesterase inhibitor, an adenosine receptor antagonist, and a xanthine. Therefore we conducted similar studies using IBMX, a phosphodiesterase inhibitor with much lower activity toward adenosine receptors. Because IBMX requires a solvent (0.1% DMSO) in order to dissolve in an aqueous medium, we compared untreated cells to cells exposed to DMSO alone, and to cells exposed to IBMX in DMSO vehicle (Fig. 4). With a 24h exposure, 1 mM IBMX evoked 80% inhibition of DNA synthesis, much greater than that seen at the same concentration of theophylline. Nevertheless, IBMX elicited only a 10% reduction in cell number, no greater than that seen with the much less effective theophylline treatment. Indeed, when compared to 10 mM theophylline, a concentration that produced roughly equivalent inhibition of DNA synthesis to that caused by 1 mM IBMX, the effect of IBMX on cell number was significantly less: 9 ± 3% reduction for IBMX, 26 ± 1% reduction for theophylline ($p < 0.0001$).

In our previous work (9), we showed that stimulation of cellular cAMP levels with a β-adrenoceptor agonist led to reductions in DNA synthesis, accompanied by desensitization at the level of receptor-mediated adenylyl cyclase activity. Accordingly, we evaluated whether theophylline, which inhibits cAMP breakdown, also targets the function of this signaling cascade. After a 48h exposure to 10 mM theophylline, basal adenylyl cyclase activity was significantly reduced but signaling mediated by the β-adrenoceptor stimulant, isoproterenol, was maintained. Similarly, the response to fluoride, which evokes maximal stimulation of the G-proteins that link the receptors to adenylyl cyclase, was unaffected despite the lowering of basal enzyme activity. The response to manganese, which stimulates adenylyl cyclase directly, without the requirement for receptors or G-proteins, was significantly enhanced by theophylline treatment.

DISCUSSION

In our previous work with MDA-MB-231 cells, we found that increasing the intracellular cAMP concentration led to a decrease in mitosis, so that membrane-permeable cAMP analogs, a β-adrenoceptor agonist (isoproterenol), or a phosphodiesterase inhibitor (theophylline), all led to a decrease in cell number (9). However, theophylline was far more effective than any other treatment and moreover, induced major morphologic changes not seen with the other agents. The current results indicate that theophylline has collateral actions that affect cell number and differentiate state. A comparison of the results of inhibition of DNA synthesis by theophylline, and the eventual reduction in cell number, provides the first indication of these additional effects. Based on the observed doubling time of MDA-MB-231 cells under our culture conditions, complete mitotic arrest for a 48h span would result in a 35-40% deficit in total cell number. However, 10 mM theophylline caused a significantly greater reduction: at 48h, the theophylline had only 40% of the control cell number; by 72h, measurements of DNA content indicated a deficit of over 80%, whereas mitotic arrest predicts only a 50% deficit. The unexpectedly large deficit in cell number is even more impressive in light of the fact that theophylline did not cause complete mitotic arrest, but rather elicited only 60% inhibition in the initial exposure period. Indeed, the fact that theophylline's effects on DNA synthesis intensify over a 24h span, implies that subsequent cellular changes are occurring that impact on cell division.

These results suggest that theophylline impacts events over and above the direct effect on cAMP and hence on cell replication. Our findings for protein synthesis and viability confirm this conclusion. Protein synthesis was reduced after a 24h exposure to theophylline at concentrations that did not affect DNA synthesis; furthermore, the entire concentration-response curve for effects on protein synthesis differed from that on DNA synthesis, as the maximal effect toward protein was considerably less. The studies with cell attachment and trypan blue exclusion provide further evidence that theophylline has an effect on cell viability in addition to its effects on replication. Theophylline exposure more than doubled the proportions of detached cells and of nonviable cells. It is unlikely that increased cAMP levels consequent to phosphodiesterase

10

inhibition, can solely account for these findings; when we compared the effects of theophylline with those of IBMX, another xanthine-based, phosphodiesterase inhibitor, we obtained results indicative of actions separable from those on cAMP. A concentration (1 mM) of IBMX that produced inhibition of DNA synthesis equivalent to that seen with 1-10 mM theophylline failed to evoke a decrease in cell number beyond what would have been expected from mitotic inhibition, a situation very different from the effects of theophylline.

There are two likely supplementary mechanisms for theophylline's actions on cell viability: formation of oxidative free radicals, and actions at adenosine receptors. Theophylline is a substrate for xanthine oxidase, an enzyme known to generate free radicals and resultant cell damage (26-29). However, IBMX is also a xanthine and similarly induces free radical formation (26). Thus, either theophylline is more potent than IBMX in eliciting oxidative stress, or alternatively, it elicits cytotoxicity through collateral mechanisms, such as actions on adenosine receptors (25). Indeed, free radicals produced by xanthine oxidase tend to increase cancer cell adhesion (27), whereas a decrease was seen with theophylline in MDA-MB-231 cells, implying that free radicals alone cannot account for all aspects of theophylline's cytotoxicity. The alternative, namely a role of adenosine receptors in cancer cell replication, differentiation and cytotoxicity has been explored only sporadically. Activation of the receptors reduces cell replication (24) and theophylline, acting as an antagonist, might then be expected to enhance, not inhibit mitosis. However, recent work indicates that under varying conditions of cell differentiation, theophylline derivatives possess mixed agonist-antagonist properties that can contribute to cytotoxicity (25). It is thus likely that the effects of theophylline on MDA-MB-231 cells represents the summation of three different mechanisms: phosphodiesterase inhibition, free radical formation, and actions at adenosine receptors.

All three mechanisms are also likely to contribute to the distinct changes in cell morphology and function seen after theophylline exposure (9). Oxidative stress itself induces cell differentiation (33); since the increase in cAMP evoked by phosphodiesterase inhibition also serves to switch cells from replication to differentiation (4-9), the combined effect can account

for the profound change in morphology evoked by theophylline but not by treatments that have more modest effects restricted only to cAMP (9). The morphological changes elicited by theophylline suggest a profound change in differentiation state, and we obtained evidence for altered cell reactivity after theophylline exposure, another characteristic of differentiation. The adenylyl cyclase signaling cascade undergoes substantial changes during growth of MDA-MB-231 cells, characterized by a loss of basal enzyme activity but preservation of signaling mediated through membrane-bound β-adrenoceptors (9). Treatment of the cells with theophylline similarly evoked a decrease in basal enzyme activity with maintenance of the response to stimulation of β-adrenoceptors by isoproterenol, or to fluoride-induced stimulation of the G-proteins that couple the receptors to adenylyl cyclase. Furthermore, there was specific enhancement of the response to manganese, which operates directly on adenylyl cyclase itself, without the participation of receptors or G-proteins; this implies either that adenylyl cyclase is induced by theophylline, or alternatively, that there is a shift toward expression of a more active isoform. In either case, the promotional effect on adenylyl cyclase is likely to augment the effects of theophylline on cAMP generation, augmenting the effect of phosphodiesterase inhibition. The induction of adenylyl cyclase and preservation of the β-adrenoceptor effect throughout differentiation may contribute additionally to the maintained ability of isoproterenol to inhibit MDA-MB-231 cell replication in the face of receptor downregulation that would ordinarily limit the response, thus augmenting the antitumor effect of other potential therapeutic interventions (9).

The multiple pharmacologic properties of theophylline, producing mitotic inhibition, cytotoxicity and altered signaling in MDA-MB-231 cells, may provide insight into novel therapeutic strategies. In light of the antitumor effects seen here, it may be worthwhile to reexamine the potential chemotherapeutic use of xanthine derivatives.

REFERENCES

1. Re G, Badino P, Girardi C, Di Carlo F: Effects of a β_2-agonist, clenbuterol, on cultured human (CG-5) breast cancer cells. Pharmacol Res 26:377-384, 1992

2. Draoui A, Vandewalle B, Hornez L, Revillion F, Lefebvre J: β-Adrenergic receptors in human breast cancer: identification, characterization and correlation with progesterone and estradiol receptors. Anticancer Res 11:677-680, 1991

3. Fentiman IS, Duhig T, Griffiths AB, Taylor-Papadimitriou J: Cyclic AMP inhibits the growth of human breast cancer cells in defined medium. Mol Biol Med 2:81-88, 1984

4. Shmukier YB, Buznikov GA: Functional coupling of neurotransmitters with second messengers during cleavage divisions: facts and hypotheses. Perspect Dev Neurobiol 5:469-483, 1998

5. Fennell M, Khawaja XZ, Cockett MI, Wood A: Enhanced neuronal differentiation of NTera-2 cells expressing neuronally restricted β_2 adrenergic receptor. Brain Res 799:243-249, 1998

6. Claycomb WC: Biochemical aspects of cardiac muscle differentiation. J Biol Chem 251:6082-6089, 1976

7. Mitra SP, Carraway RE: Synergistic effects of neurotensin and β-adrenergic agonist on 3',5'-cyclic adenosine monophosphate accumulation and DNA synthesis in prostate cancer PC3 cells. Biochemical Pharmacology 57:1391-1397, 1999

8. Chen J, Bander JA, Santore TA, Chen Y, Ram PT, Smit MJ, Iyengar R: Expression of Q227L-$G_{\alpha s}$ in MCF-7 human breast cancer cells inhibits tumorigenesis. Proc Natl Acad Sci 95:2648-2652, 1998

9. Slotkin TA, Zhang J, Dancel R, Garcia SJ, Willis C, Seidler FJ: β-Adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells. Breast Canc Res Treat in press, 2000

10. Ling L, Haraguchi K, Ohta K, Endo T, Onaya T: β_2-Adrenergic receptor mRNA is overexpressed in neoplastic human thyroid tissues. Endocrinology 130:547-549, 1992

11. Re G, Badino P, Novelli A, Girardi C, DiCarlo F: Evidence for functional β-adrenoceptor subtypes in CG-5 breast cancer cells. Pharmacol Res 33:255-260, 1996

12. MacEwan DJ, Milligan G: Up-regulation of a constitutively active form of the β_2-adrenoceptor by sustained treatment with inverse agonists but not antagonists. FEBS Lett 399:108-112, 1996

13. Canova C, Baudet C, Chevalier G, Brachet P, Wion D: Noradrenaline inhibits the programmed cell death induced by 1,25-dihydroxyvitamin D-3 in glioma. Eur J Pharmacol 319:365-368, 1997

14. Vandewalle B, Revillion F, Lefebvre J: Functional β-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 116:303-306, 1990

15. Marchetti B, Spinola PG, Pelletier G, Labrie F: A potential role for catecholamines in the development and progression of carcinogen-induced mammary tumors: hormonal control of β-adrenergic receptors and correlation with tumor growth. J Steroid Biochem Mol Biol 38:307-320, 1991

16. Vazquez SM, Pignataro O, Luthy IA: α_2-Adrenergic effect on human breast cancer MCF-7 cells. Breast Canc Res Treat 55:41-49, 1999

17. Yand J, Guzman R, Richards J, Imagawa W, McCormick K, Nandi S: Growth factor and cyclic nucleotide-induced proliferation of normal and malignant mammary epithelial cells. Endocrinology 107:35-41, 1980

18. Weishaar RE, Cain MH, Bristol JA: A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem 28:537-545, 1985

19. Sandlund JT, Neckers LM, Schneller HE, Woodruff LS, Magrath IT: Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences. Cancer Res 53:127-132, 1993

20. Francis J, Thompson R, Bernal SD, Luk GD, Baylin SB: Effects of dibutyryl cyclic adenosine 3':5'-monophosphate on the growth of cultured human small-cell lung carcinoma and the specific cellular activity of L-dopa decarboxylase. Cancer Res 43:639-645, 1983

21. Lentini A, Kleinman HK, Mattioli P, Autuori-Pezzoli V, Nicolini L, Pietrini A, Abbruzzese A, Cardinali M, Beninati S: Inhibition of melanoma pulmonary metastasis by methylxanthines due to decreased invasion and proliferation. Melanoma Res 8:131-137, 1998

22. Shafie S, Brooks SC: Effect of prolactin on growth and the estrogen receptor level of human breast cancer cells (MCF-7). Cancer Res 37:792-799, 1977

23. Goto T, Matsushima H, Kasuya Y, Hosaka Y, Kitamura T, Kawabe K, Hida A, Ohta Y, Simizu T, Takeda K: The effect of papaverine on morphologic differentiation, proliferation and invasive potential of human prostatic cancer LNCaP cells. Intl J Urol 6:314-319, 1999

24. Lelievre V, Muller JM, Falcon J: Adenosine modulates cell proliferation in human colonic adenocarcinoma. I. Possible involvement of adenosine A1 receptor subtypes in HT29 cells. Eur J Pharmacol 341:289-297, 1998

25. Brooke SM, Sapolsky RM: A cautionary note: the actions of adenosine agonists and antagonists may be reversed under certain conditions in primary cultures. Brain Res Bull 51:307-312, 2000

26. Villiotou V, Deliconstantinos G, Nitric oxide, peroxynitrite and nitroso-compounds formation by ultraviolet A (UVA) irradiated human squamous cell carcinoma: potential role of nitric oxide in cancer prognosis. Anticancer Res 15:931-942, 1995

27. Suzuki K, Eguchi H, Koh YH, Park YS, Taniguchi NT, Acceleration of adhesion of cancer cells and neutrophils to endothelial cells in the absence of de novo protein synthesis: possible implication for involvement of hydroxyl radicals. Biochem Biophys Res Comm 257:214-217, 1999

28. Maeda H, Akaike T: Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Moscow) 63:854-865, 1998

29. Yoshikawa T, Kokura S, Tainaka K, Naito Y, Kondo M: A novel cancer therapy based on oxygen radicals. Cancer Res 55:1617-1620, 1995

30. Bell JM, Whitmore WL, Slotkin TA: Effects of α-difluoromethylornithine, a specific irreversible inhibitor of ornithine decarboxylase, on nucleic acids and proteins in developing rat brain: critical perinatal periods for regional selectivity. Neuroscience 17:399-407, 1986

31. Chaudhry A, Granneman JG: Developmental changes in adenylyl cyclase and GTP binding proteins in brown fat. Amer J Physiol 261:R403-R411, 1991

32. Navarro HA, Kudlacz EM, Slotkin TA: Control of adenylate cyclase activity in developing rat heart and liver: effects of prenatal exposure to terbutaline or dexamethasone. Biol Neonate 60:127-136, 1991

33. Katoh S, Mitsui Y, Kitani K, Suzuki T: Hyperoxia induces the differentiated neuronal phenotype of PC12 cells by producing reactive oxygen species. Biochem Biophys Res Commun 241:347-351, 1997

FIGURE LEGENDS

Fig. 1. DNA synthesis and content after 2 or 24h of theophylline exposure. Data represent means and standard errors obtained from 7-16 determinations at each concentration and time. Control [^{3}H]thymidine incorporation averaged 6000 dpm/μg DNA at 2h and 5100 at 24h; DNA content averaged 26 and 33 μg/dish, respectively. ANOVA across all concentrations and both time periods appears at the top of each panel, and asterisks denote individual values that differ from the corresponding control.

Fig. 2. Effects of 10 mM theophylline on protein synthesis, measured after a 24h exposure. Data represent means and standard errors obtained from 8 determinations at each concentration. Control [^{3}H]leucine incorporation averaged 700 dpm/μg DNA. ANOVA across all concentrations appears at the top of the panel, and asterisks denote individual values that differ from the corresponding control.

Fig. 3. Cell number and viability after prolonged theophylline exposure. Data represent means and standard errors obtained from 16 determinations. Viability was determined by exclusion of trypan blue.

Fig. 4. DNA synthesis and content after exposure to 1 mM IBMX. Data represent means and standard errors obtained from 10 determinations for each condition. Because 0.1% DMSO vehicle was required to dissolve IBMX, values are compared for untreated cells (control), vehicle, and IBMX. ANOVA across all conditions appears at the top of the panel, and asterisks denote individual values that differ from the corresponding control or DMSO values.

Fig. 5. Effects of exposure to 10 mM theophylline on adenylyl cyclase activity measured under basal conditions, or with addition of 100 μM isoproterenol, 10 mM sodium fluoride, or 10 mM manganese chloride. Data represent means and standard errors obtained from 6 determinations for each stimulant. Control activities were: basal, 27 pmol/min per mg protein; isoproterenol, 70; fluoride, 59; manganese, 73. ANOVA across all measures appears at the top of the panel and asterisks denote individual values that differ from the corresponding control.

FIGURE 1

Effects of Theophylline on DNA Synthesis
ANOVA: Treatment, p < 0.0001; Treatment x Time, p < 0.0001

Effects of Theophylline on DNA Content
### ANOVA: Treatment, p < 0.0001; Treatment x Time, p < 0.0001

FIGURE 2

Effects of Theophylline on Protein Synthesis
ANOVA: Treatment, p < 0.0001

FIGURE 3

Number of Cells

p < 0.0001

millions

Control   Theophylline
                 10 mM, 48 h

Percentage Detached

p < 0.0001

% detached

Control   Theophylline
                 10 mM, 48 h

Percentage Nonviable

p < 0.0001

% nonviable

Control   Theophylline
                 10 mM, 48 h

FIGURE 4

Effects of IBMX on DNA Synthesis and Content

ANOVA: Synthesis, p < 0.0001; Content, p < 0.002

FIGURE 5

Effects of Theophylline on Adenylyl Cyclase

ANOVA: Treatment x Measure, p < 0.0001

REPLY TO
ATTENTION OF

MCMR-RMI-S   (70-1y)   15 May 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA   22060-6218

SUBJECT: Request Change in Distribution Statement

1.   The U.S. Army Medical Research and Materiel Command has
reexamined the need for the limitation assigned to technical
reports written for this Command.   Request the limited
distribution statement for the enclosed accession numbers be
changed to "Approved for public release; distribution unlimited."
These reports should be released to the National Technical
Information Service.

2.   Point of contact for this request is Ms. Kristin Morrow at
DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl   PHYLIS M. RINEHART
                                  Deputy Chief of Staff for
                                     Information Management

ADB266022   ADB265793
ADB260153   ADB281613
ADB272842   ADB284934
ADB283918   ADB263442
ADB282576   ADB284977
ADB282300   ADB263437
ADB285053   ADB265310
ADB262444   ADB281573
ADB282296   ADB250216
ADB258969   ADB258699
ADB269117   ADB274387
ADB283887   ADB285530
ADB263560
ADB262487
ADB277417
ADB285857
ADB270847
ADB283780
ADB262079
ADB279651
ADB253401
ADB264625
ADB279639
ADB263763
ADB283958
ADB262379
ADB283894
ADB283063
ADB261795
ADB263454
ADB281633
ADB283877
ADB284034
ADB283924
ADB284320
ADB284135
ADB259954
ADB258194
ADB266157
ADB279641
ADB244802
ADB257340
ADB244688
ADB283789
ADB258856
ADB270749
ADB258933